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Robert F Johnson MD, MEd 
 
The interprofessional health care specialty of palliative care employs holistic evaluation and 
person-centered communication in the care of people with life-threatening illness. Palliative 
care clinicians are consulted for one or more of the following reasons: 
 
- Symptom assessment and management 
- Assistance with making difficult decisions about continued use or withdrawal of life-
sustaining interventions 
- Communication for planning the most appropriate care setting to meet 
person/family goals for end-of-life care 
- Assessment of suitability and eligibility for hospice care 
 
This resource is a compilation of previously published documents and tools useful to palliative 
care clinicians in preparing for and conduction these consultations.  In addition, it can be a 
reference for students and clinical trainees doing course work, analyzing case studies, or 
simulating clinical communication scenarios.  The materials are indexed for easy retrieval, 
referenced to acknowledge sources and allow further exploration, and organized into the 
following categories: 
 
- Palliative Care Definitions/Domains/Dimensions 
- Communication  
- Symptom Assessment 
- Functional Status Evaluation 
- Prognostication 
- End-of-Life Assessment and Management 
- Symptom Management 
- Hospice Eligibility Criteria 
- Withholding and Withdrawing Life-Sustaining Interventions 
- Pediatric End-of-Life Issues 
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Selected Abbreviations 
ACEI = angiotensin-converting enzyme inhibitor 
ADL = Activities of Daily Living 
ALS = Amyotrophic Lateral Sclerosis 
BIS = Burden of Illness Score 
Ca++ = Calcium level 
CCI = Charlson Comorbidity Index 
CD4 = cluster of differentiation 4 (category of white blood cell – lymphocyte)  
CDT = Clock-Drawing Test 
CHF = Congestive Heart Failure 
CLL = Chronic Lymphocytic Leukemia 
CML = Chronic Myelocytic Leukemia 
CNS = Central Nervous System 
CPR = cardiopulmonary resuscitation 
COPD = Chronic Obstructive Pulmonary Disease 
DIC = Disseminated Intravascular Coagulation 
DNAR = Do-Not-Attempt-Resuscitation 
DVT = Deep Vein Thrombosis 
ECOG = Eastern Cooperative Oncology Group 
EF = ejection fraction, cardiac 
EOL = End-of-Life 
ESRD = End-stage Renal Disease 
FAST = Functional Assessment STaging (dementia) 
FEV1 = Forced Expiratory Volume 1 Second 
GCS = Glasgow Coma Scale 
Greater Than (>), Less Than (<) 
HD = hemodialysis 
Hgb = hemoglobin level 
HIV = Human Immunodeficiency Virus 
IABP = Intra-Aortic Balloon Pump 
IADL = Instrumental Activities Daily Living 
KPS = Karnosky Performance Scale 
KS = Kaposi sarcoma 
LDH = Lactic DeHydrogenase level 
LVAD = Left Ventricular Assist Device 
MBO = Malignant Bowel Obstruction 
MRIS = Mortality Risk Index Score 
m-R = modified Rankin score 
MAC = mycobacterium avium complex 
NCF = National Consensus Project for Quality Palliative Care 
NIPPV = Non-Invasive Positive Pressure Ventilation 
NHL = Non-Hodgkins Lymphoma 
NQF = National Quality Forum  
NSAID = Non-steroidal anti-inflammatory drug 
NSCLC = Non-Small Cell Lung Cancer  
NYHA = New York Heart Association 
PAD = Pain/Agitation/Delerium 
PaP = Palliative Prognostic Score 
PC = Palliative Care 
PACD = Palliative Care for Advanced Disease  
PCN = Palliative Care Notes 
PE = Pulmonary Embolism 
PIMOA = Prognostic Index 1-yr Mortality Older Adults 
plt = platelet level 
PPI = Palliative Prognostic Index 
PPS = Palliative Performance Scale 
QOL = Quality of Life 
QTc = corrected QT interval on ECG 
RASS = Richmond Agitation-Sedation Scale 
SAS = Sedation-Agitation Scale (Riker) 
SBP = Spontaneous Bacterial Peritonitis 
SDM = Shared Decision-Making 
SCCM = Society of Critical Care Medicine 
SCLC = Small Cell Lung Cancer 
SNRI = Serotonin Norepinephrine Re-Uptake Inhibitor 
SQ = subcutaneous 
SSRI = Selective Serotonin Re-Uptake Inhibitor 
TCA = Tri-Cyclic Anti-Depressant 
UDT = urine drug/toxin screen 
WBC = White Blood Cell count 
WWLST = Withholding/Withdrawing Life-Sustaining Treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
WHO Definition of Palliative Care      8 
Palliative care is an approach that improves the quality of life of patients and their families facing the problem 
associated with life-threatening illness, through the prevention and relief of suffering by means of early 
identification and impeccable assessment and treatment of pain and other problems, physical, psychosocial and 
spiritual. Palliative care: 
• provides relief from pain and other distressing symptoms; 
• affirms life and regards dying as a normal process; 
• intends neither to hasten or postpone death; 
• integrates the psychological and spiritual aspects of patient care; 
• offers a support system to help patients live as actively as possible until death; 
• offers a support system to help the family cope during the patients illness and in their own bereavement; 
• uses a team approach to address the needs of patients and their families, including bereavement 
counselling, if indicated; 
• will enhance quality of life, and may also positively influence the course of illness; 
• is applicable early in the course of illness, in conjunction with other therapies that are intended to 
prolong life, such as chemotherapy or radiation therapy, and includes those investigations needed to 
better understand and manage distressing clinical complications. 
WHO Definition of Palliative Care for Children 
Palliative care for children represents a special, albeit closely related field to adult palliative care. WHO’s 
definition of palliative care appropriate for children and their families is as follows; the principles apply to other 
pediatric chronic disorders (WHO; 1998a): 
• Palliative care for children is the active total care of the child's body, mind and spirit, and also involves 
giving support to the family. 
• It begins when illness is diagnosed, and continues regardless of whether or not a child receives 
treatment directed at the disease. 
• Health providers must evaluate and alleviate a child's physical, psychological, and social distress. 
• Effective palliative care requires a broad multidisciplinary approach that includes the family and makes 
use of available community resources; it can be successfully implemented even if resources are limited. 
• It can be provided in tertiary care facilities, in community health centers and even in children's homes. 
 
Definition of palliative care (English): European Association for Palliative care 
Palliative care is the active, total care of the patients whose disease is not responsive to curative treatment. Control of 
pain, of other symptoms, and of social, psychological and spiritual problems is paramount. 
Palliative care is interdisciplinary in its approach and encompasses the patient, the family and the community in its 
scope. In a sense, palliative care is to offer the most basic concept of care – that of providing for the needs of the 
patient wherever he or she is cared for, either at home or in the hospital. 
Palliative care affirms life and regards dying as a normal process; it neither hastens nor postpones death. It sets out 
to preserve the best possible quality of life until death. 
Definition of Hospice and Palliative Medicine – AAHPM      9 
Palliative care focuses on improving a patient’s quality of life by managing pain and other distressing symptoms of a 
serious illness. Palliative care should be provided along with other medical treatments. Hospice is palliative care for 
patients in their last year of life. Hospice care can be provided in patients’ homes, hospice centers, hospitals, long-
term care facilities, or wherever a patient resides. Physicians who specialize in hospice and palliative medicine work 
with other doctors and healthcare professionals; listen to patients and align their treatments with what’s important to 
them; and help families navigate the complex healthcare system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EPEC Dimensions of Whole Patient Assessment      10 
Nine Dimensions of Whole Patient Assessment for Palliative Care 
1. Illness, Treatment – Summary 
2. Physical 
3. Psychological 
4. Decision-Making 
5. Communication 
6. Social 
7. Spiritual 
8. Practical 
9. Anticipatory Planning 
Perspectives on a Suffering Person 
1. Disease – what a person has 
2. Dimension – what a person is 
3. Behavior – what a person does 
4. Life Status – what a person wants 
 
National Consensus Project for Quality Palliative Care (NCF) – National Quality Forum (NQF) Domains: 
1. Structure/Process 
2. Physical 
3. Psychologic/Psychiatric 
4. Social 
5. Spiritual/Existential/Religious 
6. Cultural 
7. Care of Imminently Dying 
8. Ethical/Legal 
 
NCF:  Palliative care means patient- and family-centered care that optimizes QOL by anticipating, 
preventing, and treating suffering.  Palliative care throughout the continuum of illness involves 
addressing physical, emotional, emotional, social, and spiritual needs – and to facilitate patient 
autonomy, access to information, and choice. 
 
 
 
 
 
 
 
 
 
 
Palliative Care for Advanced Disease (PCAD)       11 
 
PCAD Introduction  
  
 
  
  
  
  
 
 
Purpose of PCAD: 
 
The Goals of PCAD are to: 
 Respect patient autonomy, values, and decisions 
 Continually clarify the goals of care 
 Minimize symptom distress at the end of life 
 Optimize appropriate supportive interventions and consultations 
 Reduce unnecessary interventions 
 Support families by coordinating services 
 Eliminate unnecessary regulations 
 Provide bereavement services for families and staff 
 Facilitate the transition to alternative care settings, such as hospice, when appropriate 
 
 
PCAD consists of three components (forms are available in .pdf format):  
 PCAD Care Path – the interdisciplinary plan of care 
 PCAD Daily Patient Care Flowsheet – an interdisciplinary documentation tool for daily 
assessments and interventions 
 PCAD Healthcare Provider/MD-Order Sheet – a documentation tool and suggestions for 
symptom control approaches 
 
 
Process for utilization of PCAD Pathway (See Flowchart below): 
 
Step 1: Patient Identification 
Identification of a patient that is likely to die during this hospitalization (i.e., likely to die within 
minutes to days) by any staff member. Any staff member or others listed may suggest a patient 
for PCAD.  
 
           12 
Step 2: Interdisciplinary Assessment 
Interdisciplinary assessment of the patient for PCAD and 
discussion with the primary healthcare provider – The unit 
leadership assesses the appropriateness of the patient for PCAD 
and initiates an order for PCAD with the primary healthcare 
provider.  
 
Step 3: Provider Clarification 
Clarification of goals of care with the patient/family by the primary 
healthcare provider – The primary healthcare provider clarifies the 
goals of care with the patient and/or family and orders PCAD if 
end-of-life supportive care is the primary goal of care.  
 
Step 4: Implementation 
The primary healthcare provider orders PCAD using the PCAD 
Provider Order Sheet and rewrites the orders for the patient. 
Nurses complete the demographic information on the PCAD 
Pathway and initiate a PCAD Daily Patient Care Flowsheet.  
 
Step 5: Discharge 
The patient is discharged to an alternative care setting or dies on 
unit. A family bereavement policy is initiated (e.g., condolence 
card and educational materials sent) and a staff debriefing session 
is conducted. 
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Brief Consultation Outline      15  
 
 
Name/Service, Attending,  Patient Name/#, Requesting/Reason/Date 
 
Palliative Care Assessment: 
 Introduction: Age, Gender, Location, Adm Date, 1˚ Disease, CC 
 Background: Social (Family, Work, Live) 
   Psych (prior dx, coping, substances) 
   Spirit (religion, existential) 
 PMH:  Med, Surg, Allergies, incoming Meds 
 1˚Disease: Dx, Rx, current Status, Adv Directive, Code Status 
 Symptoms: Describe, Assess 
Pain 
    Fatigue 
      Sedation, Drowsiness 
Sleep Disturbance 
    Appetite, Dysphagia, Wt Loss 
    N/V, Constipation, Diarrhea 
    Incontinence 
    Itch 
    Depression, Anxiety 
    Hallucination, Myoclonus, Seizure 
 Exam:  VS 
   Cachexia, Wt Loss, Overt Manifestation of 1˚ Disease 
   Cognition/Delerium 
   Mouth, Nodes, Chest, Heart, Abd, Skin, Extremities, Neuro 
   Describe Painful Locations 
 Other Info: Relevant Labs, Imaging, Consults 
 Impressions: Palliative Care Diagnoses 
Assessment: Analysis of sx and/or perspective on communication/decision-    making 
 Recommend/Plan 
 
Assessment in Palliative Medicine – Outline 
 
Patient Who is patient? – social context 
  What is wrong? – illness, where in course of illness 
  Is patient “clear-headed” – What does patient understand? 
  What are Goals of Care? 
   Prolong survival 
   Optimize function 
   Optimized comfort 
  What are consequences – How are you coping? 
   Physical/psychological/social/existential 
  What are deeper thoughts/future problems    16 
Family 
  Who is family? – social context 
  What is physical/psychological well-being of family? 
  Coping? 
  What are deeper thoughts/future problems/other losses in past? 
HCP 
  Who is involved? 
  ? expertise/experience/understanding of illness 
Care Plan 
  Medical condition/Goals of care 
  Patient/family issues 
   Physical 
   Psychological 
   Spiritual/existential 
   Social 
   Communication/decision-making 
   Understanding  
  HCP issues 
   Staffing 
   Training 
   Resources 
   Emotional coping 
  Coping assessment 
   Patient 
   Family 
   HCP 
  Contingency planning 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
17 
Patient-Centered Communication (PCC): Goal is Shared Decision-Making (SDM) 
 
       Issues/Discussion Points Strategies 
Elements:  Setting    Environment/Introductions “Warning Shot” 
   Assess P/F Perspective  (Start Here) 
     (P/F=Patient/Family)  Condition   Active listening 
       Implication   “Tell-Me-More” 
       Values/Goals/Preferences       “Most Important” 
       Information/Decision Style 3 Levels 
     
   Exchange Information  Diagnosis           Correlate to V/G/P 
       Prognosis   “Ask-Tell-Ask” 
       Bad News 
       Options 
        Curative 
        Palliative 
        Hospice 
        EOL/LSI/DNAR 
     
   Respond to Emotion      “NURSE” 
   Manage Uncertainty 
Acknowledge   “Best-Worst” 
 Hope-Address/Reframe  “Hope-Worry” 
       Nonabandonment  
   Summary/Recap  (Finish Here) 
Information 
       Goals/Preferences 
       Decision(s) 
       Plan(s) 
       Follow-up 
        
Shared Decision-Making: Overall Purpose: Mutual/shared Understanding 
       Mutual/shared Goals and Plan 
       Healing Relationship 
 
“VALUE”     “ASCEND” A nticipate (pre-planning) 
V alue Patient/family statements    S ummarize (understanding) 
A cknowledge emotion/uncertainty    C oncerns   (acknowledge) 
L isten        E xplore, Explain (information, goals) 
U nderstand       N ext steps 
E licit questions       D ocument 
 
           18 
SPIKES:  “Bad News” format (and a “roadmap” for PCC communication event) 
S: Setting   “Set-up”:  Preparation/Planning 
    Environment/Comfort 
    Avoid Distractions 
    Participants/Introductions 
    “Warning Shot” 
 
P: Patient/Family  ? Perception of current status 
    Perspective  ? Expectations 
    ? Misunderstanding/Misconception/Denial 
    Values/Goals 
 
I: Invitation  Type/Extent of Information (Prognosis) 
 
K: Knowledge  Gauge to individual 
    Direct/Avoid Jargon 
    Small “Chunks” 
    Ask-Tell-Ask 
    Relate information to values/goals 
    Address decision points 
     Overall goals 
     Necessary specifics (eg DNR) 
E: Emotion/Uncertainty  Respond to Emotion 
    (NURSE mnemonic) 
    Manage Uncertainty 
S: Summary   Summarize 
    Assess Understanding 
    Strategy/Next Steps 
    Follow-up 
    Nonabandonment 
______________________________________________________________________________  
NURSE:  Responding to Emotion 
N: Name    Suggestive rather than Declarative 
      (“it sounds like…..”) 
     Active Listening 
     Restate/Summarize 
 
U: Understand   Exploration/Active Listening/Appropriate Silence 
      (“I’m understanding you to say……”) 
      (“I cannot imagine what it is like….”) 
     Avoid Premature Reassurance 
 
R: Respect    Acknowledge/Respect Intensity of Emotion 
Normalize 
Praise Coping Skills 
     Non-Verbal Cues Important 
    
S: Support    Expression of Concern 
     Articulate Understanding 
     Willingness to Help/Partner 
     Nonabandonment 
   
E: Explore    (“tell me more….”) 
     Empathy (contrasted with sympathy) 
      (“I…..you….”) 
UFO-UFO           19 
Understand: elicit patient’s understanding of their medical situation 
  Listen for gaps in knowledge, mixed messages 
  Choose your words to match theirs 
  Listen for concrete vs abstract thinking styles 
 
  “I’m wondering if you could tell me what you already know about your illness” 
  What have the doctors told you about your father’s condition?” 
Fill in Gaps: add your understanding of the situation 
  May need to break bad news 
  Take time to support emotions 
   
  “Let me fill in some details” 
  I have some new information…….” 
Outcomes: elicit the range of patients desired outcomes; explore values, hopes, fears, expectations 
  Have patient describe an acceptable quality of life and function 
  Test the lower limit carefully 
  
  “Paint me a picture of what you would be able to do and enjoy” 
  “If things were a bit worse such as ______ would that be acceptable?” 
  “Are there health situations you are worried about getting stuck in?” 
  “Is there a quality of life your mother would find intolerable?” 
  Given everything that has gone on, how do you think this will most likely turn out?” 
 
Understand: find out more about the patient as a person and why they want what they want 
  “Help me understand your decision-making” 
  “Can you tell me about yourself that will help me understand you and where you’re coming from” 
  “What things are most important to you right now” 
  “Has your father or anyone in his family ever had experiences with severe illness – did he make any comments 
     about his wishes then?”  
Feasible Outcome: describe the range of outcomes you think are possible with treatment 
  May need to break bad news 
  Take time to support emotions 
 
  “Here is what we think are the possible results/outcomes of treatment – the best case scenario is ________, 
   unfortunately there is a real possibility that _______ might happen, at this point what I think is  
   most likely to happen is ________” 
 
 
If there is overlap between the lowest acceptable QOL and the feasible outcomes: 
 “Since you are telling me you (your ___) would be OK even if the best we could do is get you out of the hospital to a nursing 
 home, I recommend we try the _______, here is the plan I would recommend……….., what do you think? OR Am I understanding you  
 correctly?” 
 
If there is NO overlap between the lowest acceptable QOL and feasible outcomes: 
 “We think the best we can hope for with the most aggressive continued treatment is to get your ______ out of the hospital but 
 would still need 24 hour care in a nursing home, probably for the rest of _____ life, but  ___has said this would not be acceptable. 
 In that case, I’m sorry to say that I cannot recommend that we continue the current level of treatment.  We will not be able to get  
 _____ to a life _____ would accept.   I recommend that we focus on things we can accomplish, like ensuring the absence of pain 
 and other symptoms” 
 
 
 
 
 
 
 
Communication – Seven Steps:         20 
 Prepare 
 Establish  (patient perspective) 
 Determine  (patient/family preferences) 
 Deliver   (information) 
 Respond (emotion) 
 Establish (plan, goals) 
 
_________________________________________________________________________________ 
 
 
Decision-Making Communication Tool 
 
 Medical Indications   Patient Preferences 
  Diagnosis    Informed/involved in decisions 
  Prognosis    Plan of care 
  Intervention    Expectations 
   Risks    Resuscitation 
   Benefits 
 Symptom Management 
 Nutrition 
 
Quality of Life    Contextual Issues 
  Activities    Home 
  Relationships    Caregiver/Family 
  Emotional    Cultural 
  Spiritual    Spiritual 
       Financial 
       Legal 
       Social 
 
“how much information do you want to know about your prognosis”? 
 Wants to know:  determine specific information wanted 
    how to present: provide information with “ballpark” exception 
       “it is impossible to predict for any individual 
       with certainty but the average person with 
       your………..” 
        
 Does not want to know: assess why, acknowledge emotion, provide enough for decisions or  
     establish proxy 
 
 Ambivalent or afraid: acknowledge, explore concerns, provide options for presenting  
  
Pain Assessment – Comprehensive       21 
Patient’s self-report is the “gold” standard, alternative methods/observations if patient unable to report 
 
Pain Experience and Context 
 Location, referral, radiation 
 Intensity 
  Last 24 hours and current, rest/movement 
 Interference with activities 
  General, mood, relationships, sleep, appetite 
 Timing 
  Onset, duration course; persistent/intermittent 
 Quality 
  Aching, stabbing throbbing, pressure (somatic) 
  Gnawing, cramping, aching, sharp       (visceral) 
  Sharp, tingling, shooting      (neuropathic) 
 Aggravating/Alleviating factors 
 Other symptoms 
 Current pain management 
  Meds, how much/often, prescriber 
  Response, relief, compliance, side effects 
 Prior pain therapies 
  Reason, length of use, response,?discontinued 
 Special issues 
  Meaning/consequence for patient/family 
  Knowledge/beliefs regarding pain medications 
  Cultural, religious, spiritual, existential beliefs 
  Goals and expectations 
 Psychosocial/psychiatric 
  Prior/current substance abuse 
  Risk factors for aberrant use/diversion (environmental, social) 
  Risk factors for undertreatment 
   Peds, geriatric, minorities, female 
   History abuse, history neuropathic pain 
   Cultural factors 
 Medical history – current/prior 
  Oncologic treatment, chemotherapy, radiation, surgery 
  Other significant illnesses. Pre-existing chronic pain 
  Physical exam, labs, imaging 
>> Pain diagnosis and individualized pain treatment plan based on mutually developed goals 
 Pain diagnosis includes etiology (disease process, treatment implication) and pathophysiology 
 (somatic/visceral, neuropathic) 
 
Pain Assessment Mnemonic:   4 A’s of pain management outcome 
 W ords      A nalgesia 
 I   ntensity     A ctivities 
 L  ocation     A dverse effects  
D uration     A berrant behavior    
 A ggravating/Alleviating 
   
 
 
Pain Assessment Observations in Cognitively Impaired      22 
 
Facial Expression   frown, fright, grimace 
    forehead wrinkle, rapid blinking 
 
Vocalizations   sigh, moan, groan, grunt, chant, call out 
    noisy breathing, ask for help, verbally abusive 
 
Body Movements  rigid, tense, guarded, fidget, pace, rock 
    restricted movement; altered gait, mobility  
 
Change in Interpersonal  aggressive, combative, decreased interaction 
Interaction   inappropriate, disruptive, withdrawn 
 
Change in Activity Pattern refuse food, appetite change, increased resting, change in sleep pattern 
or Routines   stop routines, wandering 
 
Mental Status Changes  crying/tears, confusion, irritable, distressed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Pain Assessment in Critically Ill, Sedated, on Mechanical Ventilation    23 
Categories: 
   FACIAL EXPRESSION  UPPER LIMBS   COMPLIANCE WITH  
               VENTILATOR 
 
     (POINTS)     
 
             (1) 
 
relaxed    no movement   tolerating 
 
              (2) 
 
 partially tightened brow  partially bent   coughing but tolerating 
          most of time 
 
              (3) 
 
fully tightened brow   fully bent, finger flexion fighting ventilator 
 
             (4) 
 
grimacing    retracted   unable to control ventilation 
 
 
 
 
Score points for each category 
Total 5 or greater consistent with pain response 
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Memorial Pain Assessment Card        25 
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Pain Assessment in Advanced Dementia Scale (PAINAD) 
Instructions: Observe the patient for five minutes before scoring his or her behaviors. Score the 
behaviors according 
to the following chart. Definitions of each item are provided on the following page. The patient can be 
observed under 
different conditions (e.g., at rest, during a pleasant activity, during caregiving, after the administration of 
pain 
medication).          
        
Behavior  
Score 
     
1. Breathing Independent of vocalization 
0 Normal  
1 Occasional labored breathing, short periods of hyperventilation 
2 Noisy labored breathing, long periods of hyperventilation, Cheyne-Stokes 
2. Negative vocalization 
0 none 
1 occasional moan or groan, low-level speech with a major disapproving quality 
2 repeated trouble calling out, loud moaning or groaning, crying 
3. Facial expression 
0 smiling or inexpressive 
1 sad, frightened, frown 
2 facial grimacing 
4. Body language  
0 relaxed 
1 tense, distressed pacing, fidgeting 
2 rigid, fists clenched, knees pulled up or pushing away, striking out 
5. Consolability  
0 no need to console 
1 distracted or reassured by voice or touch 
2 unable to console, distract, or reassure 
TOTAL SCORE 
(Warden et al., 2003) 
Scoring: 
The total score ranges from 0-10 points. A possible interpretation of the scores is: 1-3=mild pain; 4-
6=moderate pain; 7-10=severe pain. These ranges are based on a standard 0-10 scale of pain, but have 
not been substantiated in the literature for this tool. 
Source: 
Warden V, Hurley AC, Volicer L. Development and psychometric evaluation of the Pain Assessment in 
Advanced 
Dementia (PAINAD) scale. J Am Med Dir Assoc. 2003;4(1):9-15. 
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PAINAD Item Definitions 
(Warden et al., 2003) 
Breathing 
1. Normal breathing is characterized by effortless, quiet, rhythmic (smooth) respirations. 
2. Occasional labored breathing is characterized by episodic bursts of harsh, difficult, or wearing 
respirations. 
3. Short period of hyperventilation is characterized by intervals of rapid, deep breaths lasting a short 
period of time. 
4. Noisy labored breathing is characterized by negative-sounding respirations on inspiration or expiration. 
They may 
be loud, gurgling, wheezing. They appear strenuous or wearing. 
5. Long period of hyperventilation is characterized by an excessive rate and depth of respirations lasting a 
considerable time. 
6. Cheyne-Stokes respirations are characterized by rhythmic waxing and waning of breathing from very 
deep to 
shallow respirations with periods of apnea (cessation of breathing). 
Negative Vocalization 
1. None is characterized by speech or vocalization that has a neutral or pleasant quality. 
2. Occasional moan or groan is characterized by mournful or murmuring sounds, wails, or laments. 
Groaning is 
characterized by louder than usual inarticulate involuntary sounds, often abruptly beginning and ending. 
3. Low level speech with a negative or disapproving quality is characterized by muttering, mumbling, 
whining, 
grumbling, or swearing in a low volume with a complaining, sarcastic, or caustic tone. 
4. Repeated troubled calling out is characterized by phrases or words being used over and over in a tone 
that 
suggests anxiety, uneasiness, or distress. 
5. Loud moaning or groaning is characterized by mournful or murmuring sounds, wails, or laments in 
much louder 
than usual volume. Loud groaning is characterized by louder than usual inarticulate involuntary sounds, 
often abruptly 
beginning and ending. 
6. Crying is characterized by an utterance of emotion accompanied by tears. There may be sobbing or 
quiet weeping. 
Facial Expression 
1. Smiling or inexpressive. Smiling is characterized by upturned corners of the mouth, brightening of the 
eyes, and a 
look of pleasure or contentment. Inexpressive refers to a neutral, at ease, relaxed, or blank look. 
2. Sad is characterized by an unhappy, lonesome, sorrowful, or dejected look. There may be tears in the 
eyes. 
3. Frightened is characterized by a look of fear, alarm, or heightened anxiety. Eyes appear wide open. 
4. Frown is characterized by a downward turn of the corners of the mouth. Increased facial wrinkling in 
the forehead 
and around the mouth may appear. 
5. Facial grimacing is characterized by a distorted, distressed look. The brow is more wrinkled, as is the 
area around 
the mouth. Eyes may be squeezed shut. 
Body Language 
1. Relaxed is characterized by a calm, restful, mellow appearance. The person seems to be taking it 
easy. 
2. Tense is characterized by a strained, apprehensive, or worried appearance. The jaw may be clenched. 
(Exclude 
any contractures.) 
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3. Distressed pacing is characterized by activity that seems unsettled. There may be a fearful, worried, or 
disturbed 
element present. The rate may be faster or slower. 
4. Fidgeting is characterized by restless movement. Squirming about or wiggling in the chair may occur. 
The person 
might be hitching a chair across the room. Repetitive touching, tugging, or rubbing body parts can also be 
observed. 
5. Rigid is characterized by stiffening of the body. The arms and/or legs are tight and inflexible. The trunk 
may appear 
straight and unyielding. (Exclude any contractures.) 
6. Fists clenched is characterized by tightly closed hands. They may be opened and closed repeatedly or 
held tightly 
shut. 
7. Knees pulled up is characterized by flexing the legs and drawing the knees up toward the chest. An 
overall troubled 
appearance. (Exclude any contractures.) 
8. Pulling or pushing away is characterized by resistiveness upon approach or to care. The person is 
trying to escape 
by yanking or wrenching him- or herself free or shoving you away. 
9. Striking out is characterized by hitting, kicking, grabbing, punching, biting, or other form of personal 
assault. 
Consolability 
1. No need to console is characterized by a sense of well-being. The person appears content. 
2. Distracted or reassured by voice or touch is characterized by a disruption in the behavior when the 
person is 
spoken to or touched. The behavior stops during the period of interaction, with no indication that the 
person is at all 
distressed. 
3. Unable to console, distract, or reassure is characterized by the inability to soothe the person or stop a 
behavior with 
words or actions. No amount of comforting, verbal or physical, will alleviate the behavior. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCN Pain Assessment in Patients with Active Cancer    29 
Characterize multiple dimensions of pain: 
 Intensity 
 Temporal features (onset, course, daily fluctuation, breakthrough) 
 Location, radiation 
 Quality 
 Aggravating/alleviating factors 
Understand nature of pain: 
 Cause 
 Pathophysiology 
 Pain syndrome 
Identify effects of the Pain on Quality of Life: 
 Physical function and well-being 
 Mood, coping, psychological well-being 
 Social and family relationships 
 Sleep, vitality, sexuality 
Clarify extent of malignant disease, planned intervention(s), prognosis 
Clarify nature and quality of previous testing and past treatments 
Detail medical comorbidities 
Elucidate psychiatric comorbidities: 
 Substance-use history 
 Depression/anxiety 
 Personality disorder 
Detail current interventions/medications 
Identify other need for palliative care intervention: 
 Other symptoms 
 Psychosocial/spiritual distress 
 Caregiver burden 
 Communication, care coordination, goal-setting 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCN Psychological Assessment - Ten Essential Questions    30 
1. Have you been feeling down much of the day for the past few weeks? 
2. Do you find that you don’t experience pleasure or enjoyment from your usual activities, not 
because of pain, but because you just don’t feel interested? 
(depression) 
3. During the last six months have you been nervous or worried a lot of the time about bad things 
that might happen? 
4. Has worry at night – or during the day – kept you from being able to sleep soundly? 
(anxiety) 
5. Have you experienced a past or recent loss with which you are still having some difficulty 
coping? 
(bereavement) 
6. Are you currently worried about your family members’ ability to cope with your illness? 
(relationships) 
7. Have you found that you are struggling to find a sense of purpose in your life or to feel more 
hopeful? 
8. Have you been struggling with your faith as a result of your illness? 
(existential, spiritual) 
9. What is most stressful to you about your illness?  (e.g. change in function or appearance, fear of 
dying) 
10. Circle the number below that best describes in general how much distress you have been 
experiencing in the past week including today: 
No Distress__1__2__3__4__5__6__7__8__9__10 Extremely Distressed 
 
(6+ on scale or 5+ “yes” answers > consider psych referral) 
 
 
 
 
Psychosocial Distress Mnemonic 
 B ackground (what is going on?) 
 A ffect  (how feel?) 
 T rouble (what bothers?) 
 H andle  (how cope?) 
 E mpathy 
 
Depression screen: Have you been bothered by feeling down, depressed, or hopeless? 
   Have you been bothered by a lack of pleasure in doing things?  
 
 
 
 
 
PCN Psychologic Distress – Common Areas/clinician response    31 
 
Fear of Burdening Family: 
 Ask for more information, clarify meaning 
 Identify communication barriers 
 Normalize feelings 
 Open communication 
 “disease is a burden, not you” 
 Consider family support a gift 
 
Fear of Dying/Leaving Family: 
 Stay present emotionally 
 Normalize (vs. “naturalize”) 
 Reassure regarding symptom control 
 Determine what has been done to prepare for death 
 Identify communication barriers 
 Acknowledge difficulty of communication 
 Listen more than speak 
 Acknowledge courage to speak of this issue 
 
Denial vs Approach: 
Listen, ask reflective questions 
 Clarify “accept” and “acknowledge” 
 Assess impact on family 
 Assess communication with family 
 Do not be a prognosis “hammer” 
 
 
 
 
 
 
 
 
 
 
 
 
 
 PCN Anticipatory Grief, MDD, PTSD      32 
Anticipatory Grief 
 Anticipated loss of one’s self, prepare for separation from world 
Progression of changes (emotional, social, spiritual, physical, cognitive, behavioral) through which a 
person attempts to recognize and resolve or adjust to loss of his/her own place 
   Withdrawal from family, friends 
   Sadness, crying 
   Anxiety 
   Ruminations about past 
 
MDD = Major Depressive Disorder 
 2 weeks of depressed mood or loss of interest (anhedonia) + at least four symptoms: 
  Sleep disturbance – insomnia or hypersomnia 
  Guilt, worthlessness 
  Lack of energy 
  Loss of concentration, difficulty making decisions 
  Anorexia and/or weight loss 
  Psychomotor agitation or retardation 
  Suicidal ideation 
 
-symptoms are either new or worse than before the depressive episode, and they persist for 
most of the day, nearly every day, for 2 consecutive weeks 
-episode is accompanied by clinically significant distress or impairment in social, occupational, or 
other important areas of functioning 
-symptoms are NOT due to bereavement or to physiological effect of medication, general 
medical condition, or substance abuse 
  -mood described as “depressed”, “sad”, “hopeless”, “doen in the dumps” 
 
 Dysthymia = depressed mood + hopelessness (not suicidal) 2 years or more 
 Depression NOS = does not meet other criteria but with significant impairment of functioning 
 
PTSD = Post-Traumatic Stress Disorder 
 Re-experiencing traumatic event 
 Avoidance of situations associated with event 
 Increased arousal 
 Social/occupational impairment 
  
 
 
 
 
 
 
 
 
PCN Adjustment Disorder       33 
 
Adjustment Disorder: 
Emotional and/or behavioral symptoms in response to an identifiable stressor, within 3 months of onset 
of stressor – symptoms evidenced by: 
 Marked distress in excess of what would be expected 
 Social/occupational impairment 
Stress-related disturbance does not meet criteria for another diagnosis and is not an exacerbation of 
pre-existing diagnosis; does not represent expected bereavement; once stressor has terminated, does  
not continue for more than an additional 6 months 
 
Diagnostic criteria: 
 Onset of symptoms must occur within 1 month of stressor (not unusual or catastrophic) 
 Manifests behavior disturbances found in any affective disorder (except delusions and 
hallucinations), neurotic disorder, stress-related disorder, somatoform disorder, or conduct disorder 
BUT criteria for any individual disorder not met 
 
Example symptom features: 
 Brief depressive reaction, transient, mild, less than 1 month  
 Mixed anxiety/depression 
 Predominant conduct disorder 
 Mixed disturbance of emotion and conduct 
 Prolonged depressive reaction, mild depressive state occurring in response to prolonged  
  exposure to stressful situation (not more than 2 years)     
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PCN Manic Episode/Hypomaniac Episode (Bipolar I/Bipolar II) 
Manic (Bipolar I) Episode: distinct period during which there is an abnormally and persistently 
elevated, expansive, or irritable mood lasting at least 1 week (or less if hospitalization is required 
 
Must be accompanied by at least three (3) of the following symptoms (4 if mood is only irritable);  
inflated self esteem/grandiosity, decreased need for sleep, pressurized speech, racing thoughts, 
distractibility, psychomotor agitation, excessive involvement in pleasurable activities with a higher 
potential for painful consequences, increased involvement in goal-directed activity 
 
Disturbance must be sufficiently severe to cause marked impairment in social and occupational 
functioning or to require hospitalization, or is characterized by the presence of psychotic features 
 
Symptoms not due to direct physiological effects of medication, general medical condition, or substance 
abuse 
Symptoms do not meet criteria for a mixed episode 
 
 
Hypomanic (Bipolar II) Episode:  distinct period during which there is an abnormally and persistently 
elevated, expansive, or irritable mood lasting at least 4 days 
 
Must be accompanied by at least three (3) of the following symptoms (4 if mood is only irritable);  
inflated self esteem/grandiosity, decreased need for sleep, pressurized speech, racing thoughts, 
distractibility, psychomotor agitation, excessive involvement in pleasurable activities with a higher 
potential for painful consequences, increased involvement in goal-directed activity 
 
Hypomanic episodes must be clearly different form the usual non-depressed mood and there must be a 
clear change in functioning that is not characteristic of usual functioning 
 
Changes in mood and functioning must be observable by others – in contrast to a manic episode, a 
hypomanic episode is NOT severe enough to cause marked impairment in social or occupational 
functioning, does not require hospitalization or demonstrate psychotic features 
 
Symptoms not due to direct physiological effects of medication, general medical condition, or substance 
abuse 
 
 
 
 
 
 
 
PCN Complicated Grief Questionnaire       35 
 
Likert scale for each question: 
 0: not at all 
 1: somewhat 
2: a lot 
 
1.  How much of the time are you having trouble accepting the death of a loved one? 
2. How much does your grief interfere with your life? 
3. How much are you having images or thoughts of your loved one when he or she died or 
other thoughts about the death that really bother you? 
4. Are there things that you used to do when your loved one was alive that you don’t feel 
comfortable doing any more, that you avoid?  How much are you avoiding these things? 
5. How much are you feeling cut off or distant from other people since your loved one 
died, even people you used to be close to, like family or friends? 
 
Score of 5 or greater: consider referral/evaluation/intervention 
 
Duration of symptoms 6-12 months after death 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 PCN Delerium Definition and Causes      36 
Delerium Criteria: corresponds with ICU/CAM 
  Feature 1 = acute change or fluctuating course of mental status AND 
  Feature 2 = inattention 
    Instruct to squeeze hand with letter “A” 
    SAVEAHAART 
 
    AND 
  Either Feature 3 or Feature 4 
 
  Feature 3 = Disorganized Thinking 
   Use either a or b: 
    a – will a stone (leaf) float on water 
          are there fish (elephants) in the sea 
             does 11/21 pounds weigh more than 21/11 pounds 
          can you use a hammer to pound a nail (cut wood) 
    b – hold up this many (2) fingers, now with the other hand 
  Feature 4 = altered Level of Consciousness  (RASS other than 0) 
 
Delerium Differential Diagnosis: 
 Metabolic  (Ca++, Na+, renal, hepatic, thyroid, O2, glucose) 
 Infectious  (UTI, Pneum, cellulitis, wound, IVC, CNS) 
 Comorbidity  (constipation, urine retention, PE, MI, stroke) 
 Cancer-related  (leptomeningeal, mets, RT, paraneoplastic) 
 Seizure   (complex, partial, postictal) 
 Deficiency  (B12, thiamine, HgB) 
 Recent surgery  (anesthesia, sedation) 
 Substance  (opioid, benzo, anti-Ach, anti-histamine, NSAID, steroid) 
  Multi-factorial 
 
 Terminal  (restlessness often combination of progressive disease, dehydration, 
     accumulation of metabolites from organ failure) 
 
 
 
 
 
 
 
 
 
 
PCN SAS RASS          37 
 
SAS = Sedation-Agitation Scale (Riker) 
 7 – dangerous agitation 
 6 – very agitated 
 5 – agitated 
 4 – calm, cooperative 
 3 – sedated 
 2 – very sedated 
 1 – unarousable 
 
 
RASS = Richmond Agitation-Sedation Scale 
 
 +4 combative, violent, dangerous 
 +3 very agitated, aggressive 
 +2 agitated, frequent non-purposeful movements 
 +1 restless, anxious but not aggressive or vigorous 
 
0 alert and calm 
 
-1 drowsy, not fully awake but sustains awake 10 seconds or more 
-2 light sedation, brief awake less than 10 seconds 
-3 moderate sedation, movement or eyes open to voice but no eye contact 
-4 deep sedation, no response to voice but responds to physical stimulation 
-5 unarousable, no response to voice or physical stimulation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cornell Assessment of Pediatric Delerium       38 Cut	point	analysis	showed	the	best	sensitivity	and	specificity	for	the	screening	instrument	(prioritizing	high	sensitivity)	at	a	total	CAPD	score	of	9	or	greater.	Sensitivity	was	94.1%	(95%	CI,	83.8–98.8%)	and	specificity	79.2%	(95%	CI,	73.5–84.9%).			(CCM,	3/14)	
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 Delerium Observation Screening (DOS) Scale      40 
Scoring: 0 = Never 
  1 = Sometimes or Always 
 
Observations: 
1. Dozes off during conversation or activities 
2. Is easily distracted by stimuli from the environment 
3. Does not finish question or answer 
4. Gives answers that do not fit the question 
5. Reacts slowly to instructions 
6. Thinks is somewhere else 
7. Picking, disorderly, restless 
8. Pulls IV tubing, feeding tubes, catheters etc 
9. Easily or suddenly emotional 
10. Sees/hears things which are not there 
 
Scoring: 1 = Never 
  0 = Sometimes or Always 
 
11. Maintains attention to conversation or action 
12. Knows which part of the day it is 
13. Remembers recent events 
 
 
 
Less than 3/13 = not delirious 
3/13 or greater = probably delirious 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCN Spiritual Assessment – HOPE       41 
H: sources of hope, meaning, comfort, strength, peace, love, connection 
 What gives you support? 
 What are your sources of hope….? 
 What do you hold onto during difficult times? 
 What sustains you and keeps you going? 
 For some people religious and spiritual beliefs act as a source of strength and comfort.  ? true for you 
O: organized religion 
 How important is this to you? 
 What parts are helpful and not so helpful? 
 Are you part of a faith community? 
P: personal spirituality and practices 
 Do you have personal/spiritual beliefs that are independent of organized religion? 
 Do you believe in God? 
 What aspects of your spirituality or spiritual practices do you find most helpful? 
E: effects on medical care and end-of-life issues 
 Has being sick affected the things you usually do to help you spiritually? 
 Are you worried about conflicts between your spiritual beliefs and medical care? 
 ? wish to speak to clergy 
 ? practices/restrictions to know 
 ? influence on EOL care 
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PCN Spiritual Assessment FICA Mnemonic 
 
F faith, belief, meaning 
  “do you consider yourself spiritual or religious”? 
  “do you have spiritual beliefs that help you cope with stress”? 
  “what gives your life meaning”? 
 
I importance and influence 
  “what importance does your faith or belief have on your life”? 
  “have your beliefs influenced you in how you handle stress”? 
  “do you have specific beliefs that might influence your healthcare decisions”? 
 
C community 
  “are you a part of a religious or spiritual community”? 
  “is there a group of people you really love or who are important to you”? 
 
A address/action in care 
  “how should the health care provider address these issues in health care”? 
 
 
 
Spirituality = meaning, purpose, something beyond oneself 
Qualities of being: hope, love, purpose, meaning 
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PCN Spiritual Assessment SPIRIT Mnemonic 
 
S:  spiritual belief system 
   ? formal affiliation 
   ? important 
 
P:  personal spirituality 
   ? in what ways important 
 
I:  integration with a spiritual community 
   ? belong to religious group/community 
 
R:  ritualized practices/restrictions 
   ? specific practices 
 
I:  implications for health care 
   ? discuss religious/spiritual implications of health care 
 
T:  terminal events planning 
   ? particular aspects of medical care to forego because of religion/spirituality 
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Cultural Competency and the Role of Race, Ethnicity, and 
Religion 
Physicians who practice in a multicultural environment have a responsibility to understand that 
family members from some cultures may have very different perspectives on the family’s role 
and on who should be involved in treatment decisions. Individuals from some cultures may not 
endorse tenets of Western clinical ethics, such as the equivalence of withholding and 
withdrawing life support or the definition of brain death. It is important to anticipate differences 
in perspectives and apply principles of culturally effective end-of-life care to these situations.  
Several studies of patients’ attitudes toward end-of-life care identify values that vary by race, 
ethnicity, and geographic origin. On average, nonwhites are more likely to request life-sustaining 
therapy and are less likely to have advanced directives or do-not-resuscitate orders or accept 
hospice care. Much of this difference is influenced by patients’ and families’ lack of trust in 
physicians and health-care institutions. Although understanding ethnic variations in preferences 
will not solve all problems with end-of-life care, a clearer understanding of what contributes to 
patients’ and families’ understanding, fears, and preferences improves communication and is a 
crucial step in providing better end-of-life care.  
Physicians have a responsibility to avoid stereotyping patients or making assumptions about their 
attitudes based solely on race, ethnicity, religion, or other demographic characteristics. Existing 
recommendations can help physicians provide end-of-life care that accommodates needs based 
on religion and culture.The dying process is one of the most important events in which ritual 
aspects of religion and spirituality play a role. During discussions of end-of-life care, time should 
be spent discussing, understanding, and accommodating cultural and religious perspectives, and 
reasonable efforts should be made to accommodate rituals associated with dying. Physicians 
should not assume that physician and hospital staff share the same values as patients and families 
of similar religious or ethnic background, and should not substitute statements from persons of 
similar background for a more thorough discussion with the patient and their family.  
“Cross-cultural” Mnemonics 
L earn, listen      E xplanation 
E xplain      T reatment 
A cknowledge      H ealers 
R ecommend      N egotiation 
N egotiate      I   ntervention 
       C ollaboration 
 
 
 
 
 
PCN Questions to Assess Spirituality       45 
S piritual belief system 
P ersonal spirituality 
I integration in a spiritual community 
R itualized practices and restrictions 
I mplications for medical care 
T erminal events planning 
 
Hope: “as you look to the future, what are your biggest fears”? 
 “are there things you might hope for even if you cannot be cured”? 
 “does the word hope have any spiritual significance for you”? 
 “would anything be unfinished if you were to die sooner rather than later”? 
 
Meaning: “what gives your life most meaning”? 
  “what gives you strength in difficult times”? 
  “do you have any thoughts about why this happened to you”? 
  “if your time were limited, what would be most important to you”? 
   
Values: “are you able to hold on to your sense of dignity and purpose”? 
 “how are others treating you since you became ill”? 
 
Relationships: “how is your family coping with your illness”? 
  “what is it like to be taken care of by others after being a caregiver for so long”? 
  “is there anyone you have to make amends with”? 
  “(if religious) how are things between you and God”?  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCN Spirituality (Doctrinal Justification[s] alternative)     46 
Hope for Miracle: 
 All humans are subjects to the laws of nature by the virtue of God’s sovereign rule issued for 
people; although God is not bound by the laws of nature, humans are; it is appropriate to accept a 
miracle when granted by God, but it is not appropriate to expect it, as this would imply that God follows 
human rules and not his sovereign design 
 
One Shall Not Give Up On The God Of Faith: 
 Continuing with the aggressive treatment no longer constitutes awaiting for God’s will to 
manifest itself in a miracle; rather it is interfering with God’s plan made evident in the abundantly given 
due time; withholding treatment amounts to acceptance of God’s plan 
 
Life Must Be Preserved At All Costs: 
 Life given by God is a supreme gift; yet life artificially maintained by a machine is not; the 
abundant gift of life includes a promise of presence, personhood,, and participation in the divine vision; 
the technology-dependent support of vegetative function discounts the true gift of life 
 
Suffering Is Redemption: 
 One needs capacities of personhood and free choice in order to elect participation in a 
redemptive and transformative suffering; when such a choice is made to and not for a person, suffering 
becomes an end in itself 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCN ESAS (Edmonton Symptom Assessment Scale)     47 
 
No Symptom___1___2___3___4___5___6___7___8___9___10 Worst Possible Symptom 
 
  Pain 
  Fatigue 
  dyspnea 
  Nausea 
  Constipation 
  Depression 
  Anxiety 
  Drowsiness 
  Appetite 
  Well-Being 
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PCN Mental Status Examination Terms 
 
Appearance and Behavior: 
 Grooming, clothing, hair, nails 
 Attitude to situation/examiner – hostile, withdrawn, seductive 
 Motor – slow, restless, tremors, bizarre 
Speech: 
 Slow, pressured, monotonous 
 Volume – loud, quiet, slurred 
 Quantity – restricted/excessive, spontaneous 
Mood/Affect: 
 Depressed, euphoric, suspicious, labile 
 Restricted, flattened, inappropriate 
Form of Thought: 
 Amount and rate of production – hesitant, vague, flight of ideas 
 Continuity of ideas – logical order of the flow of ideas 
Content of Thought: 
 Delusions – persecution, poisoning 
 Suicidal thoughts/plans/intent 
 Other – obsessions, compulsions, hypochondriacal preoccupation 
Perception: 
 Hallucinations – sound, vision, smell, taste, tactile, somatic 
 Other – derealization, depersonalization, heightened/dulled 
Sensorium and Cognition: 
 Level of Consciousness (LOC) – abnormal drowsiness, clouding, delirium 
 Memory – immediate recent, remote 
 Orientation – time, place, person 
 Concentration – serial 7s 
 Abstract thinking 
Insight: 
 Extent of awareness of problem(s) 
 Compliance with intervention(s) 
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PCN Abbreviated Mental Status Score 
 
1 age 
2 time (nearest hour) 
3 address (repeated at end of exam) 
4 year 
5 name of current location 
6 recognition of two persons 
7 date of birth 
8 year World War I started 
9 name of president 
10 count backwards from 20 to 1 
 
 
 
6 or less correct consistent with dementia 
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PCN Short Test of Mental Status (STMS) 
 
Orientation: 0-8 points 
  Name, address, current location (building), city, state, date (day), month 
Attention: 0-7 points 
  Present 5, then 6, then 7 digits to repeat 
   2-9-6-8-3 5-7-1-9-4-6 2-1-5-9-3-6-2 
Immediate  
  Recall: 0-4 points 
  Present four(4) unrelated words to repeat (subtract #trials needed to learn) 
   “apple, Mr Smith, charity, tunnel” 
Calculation: 0-4 points 
   5x13 65-7 58/2 29+11 
Abstraction: 0-3 points 
  Describe similarity: 
   Orange – banana 
   Dog – horse 
   Table – bookcase 
Construction and Copying: 0-4 points (2 points each) 
  Draw a clock face showing 11:10 
  Copy a cube 
Information: 0-4 points 
   President 
   1st president 
   Define an island 
   Number of weeks in a year 
Recall:  0-4 points 
   “apple, Mr Smith, charity, tunnel” 
 
38 possible points 
 
34-38 – normal 
29-33 – cognitive impairment 
28 or less - dementia 
 
 
 
 
 
 
 
 
PCN MMSE Mini-Mental-Status Exam       51 
Orientation:         Points  
 year/season/date/day/month      5 
 state/country/town/hospital/floor     5 
 
Registration: 
 name three objects – 1 second to say each 
  (i.e. ball, flag, tree) 
 ask patient to repeat all three after you have said them   3 
 
 then repeat them until patient learns all three, count trials 
 
Attention/Calculation:        5 
 serial 7’s – up to 5 answers  OR 
 spell WORLD backwards (DLROW) 
 
Recall:          3 
 ask for the three objects repeated above 
 
Language: 
 show/name a pen and watch      2 
 “repeat – no ifs, ands, or buts”      1 
 follow a 3 stage command: 
  take a paper in your hand 
  fold it in half       
  place it on the floor      3 
 read and obey 
  “CLOSE YOUR EYES”      1 
 “write a sentence”       1 
 
 “copy the design”    (intersecting pentagons)    1 
          30 
 
Cognitive Function: 
24-30 normal 
19-23 mild  
10-18 moderate 
<10 severe 
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PCN Neuro-Cognitive Behavioral Assessment Terms 
 
Mental Status 
 Oriented: aware of person, place, time, season 
 Inattention: difficult in focusing attention 
   easily distracted 
   difficulty in following conversation 
 Disorganized Thinking: 
   incoherent, rambling, irrelevant 
   unclear, illogical flow of ideas 
 Altered Level of Consciousness (LOC): 
   vigilant – startled easily 
   lethargic – repeatedly dozes off but responds to touch or voice 
   stuporous – very difficult to arouse 
   comatose – cannot be aroused 
 Psychomotor Retardation: 
   unusually decreased level of activity 
   sluggish 
   staring into space 
   sitting/lying in one position 
    
Cognitive Skills for Daily Decision-Making 
 Independent: decisions consistent and reasonable 
 Modified Independence: 
   some difficulty in new situations only 
 Moderately Impaired: 
   decisions poor 
   cues and/or supervision required 
 Severely Impaired: 
   never or rarely makes decisions 
 
 
 
 
 
 
 
 
 
 
 
 
PCN General Symptom Distress Scale (GSDS)      53 
 
1. Symptoms present: 
depression   anxiety   
fatigue    dyspnea    
nausea    vomiting  
pain    sleep difficulty 
bowel problems  difficulty concentrating 
loss of appetite   cough 
2. Rank (1,2,3,……..) of symptoms present – from most distressing to next most distressing…… 
3. On a scale of 1 to 10, in general how distressing are ALL of your symptoms to you? 
1   – not at all 
10 – extremely  
4. On a scale of 1 to 10, how well are you able to manage your symptoms? 
1 - cannot manage     
10 -   manage extremely well 
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PCN Fall Risk Assessment 
Points 
7  history of a fall within past 12 months 
3  altered elimination – incontinence, frequency, urgency 
3  cognitive impairment – inability to recall recent events 
   Confusion, impaired judgment 
3  sad, depressed 
3  intrinsic factors 
   orthostatic hypotension 
   syncope 
   arrhythmia 
   peripheral neuropathy 
   seizure history 
   parkinsons 
   hx stroke 
   neuromuscular disorder 
2   communication – HOH, language barrier, tracheostomy 
2   visual impairment 
2   diuretics or laxatives 
4   anti-hypertensive medication 
6   opioid medication 
 
Very High Risk  19 points or greater 
High Risk  14-18 points 
Medium Risk  10-13 points 
Low Risk  9 points or less 
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PCN Functional Activities Questionnaire 
Score each question on a 4 point scale: 
 0 = normal, 1 = does with difficulty, 2 = requires assistance, 3 = dependent 
 
In the past 4 weeks, did the patient have any difficulty or need help with:? 
 
1 writing checks, paying bills, keeping financial records 
2 assembling tax records, business affairs, papers 
3 shopping alone – clothes, household, groceries 
4 playing a game of skill or working on a hobby 
5 heating water, making coffee, turning off stove 
6 preparing a balanced meal 
7 keeping track of current events 
8 paying attention to, understanding, or discussing a TV program/book/magazine 
9 remembering appointment, family occasion, holiday, medication 
10 traveling out of the neighborhood, driving, arranging to take bus 
 
 
normal = 0-1 
mild cognitive impairment = 4-9 
mild dementia = 10-13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCN Spinal Cord Injury Assessment      56 
 
Level of Innervation Sensory   Muscle Group 
 
C4   acromioclavicular joint diaphragm 
C5   lateral antecubital fossa shoulder rotators/abductors; elbow flexor 
C6   thumb    supinators, pronators, wrist extensor 
C7   middle finger   elbow extensor, wrist flexor 
C8   little finger   finger flexors, distal phalanx 
 
T1   medial antecubital fossa intrinsic hand muscles 
 
L2   upper anterior thigh  hip flexor 
L3   medial femoral condyle knee extensor 
L4   medial malleolus  ankle dorsiflexor 
L5   dorsum of foot  toe extensors 
S1   lateral heel   plantar flexors 
S2-5   peri-anal   sphincter 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCN Modified Medical Research Council (mMRC) Dyspnea Scale  57 
 
0: breathless with strenuous exercise 
1: short of breath when hurrying on level ground or walking up a slight hill 
2: on level ground, walking slower than people of same age because of breathlessness 
  or have to stop for breath when walking at my own pace 
3: stop for breath after walking about 100 yards or after a few minutes on level ground 
4: too breathless to leave the house; breathless when dressing 
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Function Assessment: Activities of Daily Living (ADL) 
 
Bathing  receives either no assistance or assistance in bathing only one part of the body 
Dressing gets clothes and dresses without any assistance except for tying shoes 
Toileting goes to toilet room, uses toilet and returns without assistance 
   (may use cane or walker and may use bedpan or urinal at night) 
Transferring moves in and out of bed and chair without assistance 
   (may use cane or walker) 
Continence controls bowel and bladder completely by self, without occasional accidents 
Feeding feeds self without assistance 
(except for help with cutting meat or buttering bread) 
 
 
 
Function Assessment: Instrumental Activities of Daily Living 
 
Use telephone 
Shop 
Prepare food 
Clean house 
Laundry 
Use transportation 
Take medications 
Manage finances 
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Function Assessment 
Eastern Cooperative Oncology Group  (ECOG) 
 
Performance Status 
 
0 Fully active, able to carry out all pre-disease performance without restriction 
 
1 Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or 
sedentary nature (light house work, office) 
 
 
2 Ambulatory and capable of all self-care but unable to carry out any work activities.  Up and about 
more than 50% of waking hours 
 
3 Capable of only limited self-care, confined to bed or chair more than 50% of waking hours 
 
 
4 Completely disabled. Cannot carry out any self-care.  Totally confined to bed or chair 
 
5 Dead         
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PCN Function Assessment FAST 
Functional Assessment Staging  (dementia, cognitive impairment) 
 
5 requires assistance in choosing proper clothing to wear for day/season/occasion 
6A improperly putting on clothes without assistance 
6B unable to bathe properly occasionally or more often over past weeks 
6C inability to handle mechanics of toileting occasionally or more often over past weeks 
6D urinary incontinence occasionally or more often  
6E fecal incontinence occasionally or more often over past week 
 
7A ability to speak limited to approximately 6 words or fewer in the course of a day 
7B speech ability limited to use of a single intelligible word in a day (may be repeated) 
7C ambulatory ability is lost; cannot walk without personal assistance 
7D cannot sit up without assistance; will fall without lateral support 
7E loss of ability to smile 
7F loss of ability to hold head up independently 
 
 
Based on highest CONSECUTIVE level of disability 
5 correlates with moderate dementia 
6 correlates with moderately severe 
7 correlates with severe 
7 roughly correlates with 6 month prognosis 
 
 
 
 
 
 
 
 
 
 
 
 
PCN Function Assessment CDT        61 
Clock-Drawing Test 
Step 1 give patient a sheet of paper with a drawn large circle 
Step 2 instruct to draw numbers in the circle to look like the face of a clock; 
 then draw the hands of the clock to read “10 after 11” 
 
Scoring: 
1 perfect     no errors 
2 minor visual-spatial errors  mildy impaired spacing of numbers 
      draws numbers outside of circle 
      turns page > draws numbers upside down 
      draws with lines (“spokes”) 
 
3 inaccurate representation  minute hand points to 10 
 of 10 after 11 when visual-  writes “10 after 11” 
 spatial organization is    unable to make any notation of time 
 perfect or minor deviation   
       
4 moderate visual-spatial   moderately poor spacing 
 disorganization of times   omits numbers 
 such that accurate notation  perseveration 
 of 10 after 11 not identified  counterclockwise 
      dysgraphia 
 
5 severe level of disorganization  as in 4 
6 no reasonable representation  no attempt 
 of a clock    no semblance of a clock 
      writes a word or name 
 
(3 or greater = cognitive deficit) 
 
High NEGATIVE predictive value (95%) > normal CDT strong argument against cognitive deficit 
 
Requires comprehension, visual-spatial ability, reconstruction skills, concentration, numerical 
knowledge, visual memory, executive function; not biased by age, gender; not influenced by language 
limitation or altered mood 
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Function Assessment: Karnofsky Performance Status Score  (KPS) 
 
Karnofsky Score Level of Functional Capacity 
100   normal, no complaints, no evidence of disease 
90   able to carry out normal activity, minor signs/symptoms of disease 
80   normal activity with effort, some signs or symptoms of disease 
70   cares for self, unable to carry on normal activity or to do active work 
60   requires occasional assistance but is able to care for most needs 
50   requires considerable assistance and frequent medical care 
40   disabled, requires special care and assistance 
30   severely disabled, hospitalization indicated although death not imminent 
20   hospitalization necessary, very sick, active supportive treatment necessary 
10   moribund, fatal processes, progressing rapidly 
0   dead 
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Function Assessment: modified Rankin score (m-R) 
 
0 no symptoms 
1 no significant disability despite symptoms – able to carry out all usual activities 
2 slight disability – unable to carry out all previous activities but able to carry 
    out ADLs without assistance 
3 moderate disability – requiring some help but able to walk without assistance 
4 moderately severe disability – unable to walk without assistance and unable  
    to carry out ADLs without assistance 
5 severe disability – bedridden, incontinent, requiring constant nursing care and attention 
6 dead 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCN Glasgow Coma Scale (GCS)       64 
 
Eye opening response: 
 Spontaneous – open with blinking at baseline   4 points 
 Opens to verbal command, speech or shout   3 points 
 Opens to pain, not applied to face    2 points 
 None        1 point 
 
Verbal response: 
 Oriented       5 points 
 Confused conversation, but able to answer questions  4 points 
 Inappropriate responses, words discernible   3 points 
 Incomprehensible speech     2 points 
 None         1 point 
 
Motor response: 
 Obeys commands for movement    6 points 
 Purposeful movement to painful stimuli    5 points 
 Withdraws to pain      4 points 
 Abnormal (spastic) flexion, decorticate posture   3 points 
 Extensor (rigid) response, decerebrate posture   2 points 
 None        1 point 
         ________ 
          
         Max 15 points 
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PCN Function Assessment 
 Palliative Performance Scale (PPS) 
%:    100 
Ambulation:   Full 
Activity/Evidence of Disease: Normal/no evidence 
Self-Care:   Full 
Intake:    Normal 
LOC:    Intact 
 
%:    90 
Ambulation:   Full 
Activity/Evidence of Disease: Normal/some 
Self-Care:   Full 
Intake:    Normal 
LOC:    Intact 
 
%:    80 
Ambulation:   Full 
Activity/Evidence of Disease: Normal with effort/some 
Self-Care:   Full 
Intake:    Normal or reduced 
LOC:    Intact 
 
%:    70 
Ambulation:   Reduced 
Activity/Evidence of Disease: Unable to do normal/some 
Self-Care:   Full 
Intake:    Normal or reduced 
LOC:    Intact or confusion 
 
%:    60 
Ambulation:   Reduced 
Activity/Evidence of Disease: Unable to do hobby or some housework/significant 
Self-Care:   Occasional assist 
Intake:    Normal or reduced 
LOC:    Intact or confusion 
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%:    50 
Ambulation:   Mainly sit/lie 
Activity/Evidence of Disease: Unable to do any work/extensive 
Self-Care:   Considerable assist 
Intake:    Normal or reduced 
LOC:    Intact or confusion 
 
%:    40 
Ambulation:   Mainly in bed 
Activity/Evidence of Disease: Unable to do any work/extensive 
Self-Care:   Mainly assist 
Intake:    Normal or reduced 
LOC:    Intact, drowsy, or confusion 
 
%:    30 
Ambulation:   Bed bound 
Activity/Evidence of Disease: Unable to do any work/extensive 
Self-Care:   Total care 
Intake:    Reduced 
LOC:    Intact, drowsy, or confusion 
 
%:    20 
Ambulation:   Bed bound 
Activity/Evidence of Disease: Unable to do any work/extensive 
Self-Care:   Total care 
Intake:    Sips 
LOC:    Intact, drowsy, or confusion 
 
%:    10 
Ambulation:   Bed bound 
Activity/Evidence of Disease: Unable to do any work/extensive 
Self-Care:   Total care 
Intake:    Mouth care 
LOC:    Drowsy or coma 
 
 
Instructions for PPS 
Begin at the left column and read downward until the appropriate ambulation level is reached, then read across to the next column and 
downwards again until the activity/evidence of disease is located.  These steps are repeated until all five columns are covered before assigning 
the PPS.  Leftward columns (ambulation on left>activity level/evidence of disease>self-care>intake>LOC on right)  are “stronger” determinants 
and take precedence over others to the right.  PPS scores are in 10% increments.  Choosing a “half-fit” level (such as 45%) is not correct.  The 
combination of clinical judgment and “leftward” precedence determines the score.  PPS may be used for: communication regarding functional 
status, criterion for workload assessment or other measurements/comparisons, and as a prognostic indicator. 
Edmonton Frail Scale         67 
Domain  Item       Score 
Cognition Please imagine that this pre-drawn circle is a clock. 0 – no errors 
  Please place the numbers in the correct positions and 1- minor spacing errors 
  Then place the hands to indicate a time of   2- other errors 
  “ten past eleven” 
 
General In the past year how many times have you been  0-0, 1-1, 2- 2 or more 
Health  admitted to the hospital? 
Status 
  In general, how would you describe your health? 0-excellent, very good , or good 
         1-fair, 2-poor 
 
Functional  With how many of the following activities do you  0-1, 1-2 to 4, 2-5 to 8 
Independence help: meal preparation, shopping, transportation, 
  telephone, housekeeping, laundry, managing money, 
  taking medications? 
 
Social Support When you need help, can you count on someone who 0-always, 1-sometimes, 2-never 
  is willing and able to meet your needs? 
 
Medication Use Do you use five or more prescriptions on a regular basis? 0-no, 1-yes 
  At times do you forget to take your prescription medications? 0-no, 1-yes 
 
Nutrition Have you recently lost weight so that your clothing has   0-no, 1-yes 
  become looser? 
 
Mood  Do you often feel sad or depressed?    0-no, 1-yes 
 
Continence Do you have a problem with losing control of urine when 0-no, 1-yes 
  You don’t want to? 
 
Functional Please sit in this chair with your back and arms resting.  0-10 seconds or less 
  When I say “go”, please stand up and walk to the mark on 1-11 to 20 seconds 
  the floor (approximately 10 feet away), then turn around,  2->20 seconds or  
  return to the chair and sit down.        unwilling, unable 
Scoring: 
  0-5 not frail 
  6-7 vulnerable 
  8-9 mild frailty 
  10-11 moderate frailty 
  12-17 severe frailty 
PCN Malnutrition Categories        68 
Severe: 
 Albumin   < 2.0 g/dl 
 Prealbumin   < 5.0 mg/dl 
 Ideal body weight  <70% 
Usual body weight  <75% or * 
 BMI    <16 
 
Moderate: 
 Albumin   < 2.5 g/dl 
 Prealbumin   < 10.0 mg/dl 
 Ideal body weight  <80% 
Usual body weight  <85% 
 BMI    <17 
 
Mild: 
 Albumin   < 3.0 g/dl 
 Prealbumin   < 15.0 mg/dl 
 Ideal body weight  <90% 
Usual body weight  <95% 
 BMI    <18.5 
 
*unintended weight loss of > 5% in one month, >7.5% in 3 months, >10% in 6 months, or 
>20% in one year 
 
“chronic” malnutrition is defined as a duration of three months or more. 
At least two indicators should be present in addition to physical findings and high-risk clinical 
circumstances.  Albumin and prealbumin should be considered one indicator, not two. 
 
 
 
 
 
 
 
 
 
 
PCN Cerebral Performance Categories (CPC Scale)     69 
CPC 1: good cerebral performance – conscious, alert, able to work, might have mild neurologic or 
psychologic deficit 
CPC 2: moderate cerebral disability – conscious, sufficient cerebral function for independent activities 
of daily life, able to work in sheltered environment 
 
CPC 3: severe cerebral disability – conscious, dependent on others for daily support because of 
impaired brain function, ranges from ambulatory state to severe dementia or paralysis 
 
CPC 4: coma or vegetative state – any degree of coma without the presence of all brain death criteria; 
unawareness, even if appears awake (vegetative state) without interaction with environment, may have 
spontaneous eye opening and sleep/awake cycles, cerebral unresponsiveness 
 
CPC 5: brain death – apnea, areflexia, EEG silence 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCN Function Assessment Barthel Index      70 
Activity 
Feeding: 
 0 = unable 
 5 = needs help cutting, spreading butter etc, or requires modified diet 
                10 = independent 
Bathing: 
 0 = dependent 
 5 = independent (or in shower) 
Grooming: 
 0 = needs help with personal care 
 5 = independent face/hair/teeth/shaving 
Dressing: 
 0 = dependent 
 5 = needs help but can do about half unaided 
 10 = independent (including buttons, zips, laces) 
Bowels: 
 0 = incontinent (or needs to be given enemas) 
 5 = occasional accident 
 10 = continent 
Bladder: 
 0 = incontinent, or catheterized and unable to manage alone 
 5 = occasional accident 
 10 = continent 
Toilet Use: 
 0 = dependent 
 5 = needs some help 
 10 = independent (on and off, dressing, wiping) 
Transfers: (bed to chair and back) 
 0 = unable, no sitting balance 
 5 = major help (one or two people, physical) can sit 
 10 = minor help (verbal or physical) 
 15 = independent 
Mobility: (on level surfaces) 
 0 = immobile or less than 50 yards 
 5 = wheelchair independent, including corners, more than 50 yards 
 10 = walks with help of one person (verbal or physical) more than 50 yards 
 15 = independent 
Stairs: 
 0 = unable 
 5 = needs help (verbal, physical, carrying aid) 
 10 = independent 
 
0 – 100 points 
 
Record what patient actually does; need for supervision > not independent; usually last 24-48 hrs 
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PCN Prognostic Assessment 
Non-Disease Specific 
Population: Hospitalized, age 70 or greater 
Burden of Illness Score (BIS) 
BIS variables    BIS points 
High-risk diagnoses 
 See below   0-3 
 
Albumin < 3.5    1 
Creatinine > 1.5    1 
Dementia    1 
Walking impairment   1 
 
      (Scoring for High-risk diagnoses) 
       Variable  points 
Lymphoma  6 
       Leukemia  6 
       Acute renal failure 5 
       Cancer   3 
       Stroke   2 
       CHF   2 
       COPD   2 
       Chronic renal failure 2 
       DM with organ disease 1 
       Pneumonia  1  
      (Transfer High-risk diagnoses score to BIS: 
0 0 
        1-2   1 
        3-5   2 
        6 or greater  3  
 
Correlation of BIS Score with 1-year mortality risk % 
0-1 8 
2    24 
  3    51 
  4 or greater   74 
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Prognosis Assessment  Non-Disease Specific 
CARING criteria 
Population: Criteria on day of admission to acute care hospital 
Caring criteria components: 
C: Primary Diagnosis of Cancer 
  Cancer diagnosis is primary reason for admission including admission for chemoRx 
 
A: Admitted to the hospital 2 or more times in the past year 
  for the same chronic illness or complication of that illness 
 
R: Resident in a Long-Term Care or Skilled Nursing Facility (Nursing Home) 
 
I: ICU admission with Multiple Organ System Failure (MOF) 
  MOF = any two or more of the following 
   Mechanical ventilation 
   Pressor support for hypotension 
   Renal replacement therapy (RRT) indicated or already started 
 
NG: Presence of two or more items from one category of non-cancer hospice guidelines 
  Categories 
   Items 
 
  Renal     Dementia 
   Stop/decline dialysis    Unable to ambulate independently 
   Not transplant candidate   Urinary or fecal incontinence 
   Urine output < 40ml/24 hours   Unable to speak with more than single words 
   Creatinine > 8.0    Unable to bathe independently 
   Creatinine clearance 10 ml/min or less  Unable to dress independently 
   Uremia     One or more comorbid conditions: 
   Persistent K+ > 7.0     Aspiration pneumonitis 
   One or more comorbid conditions:   Pyelonephritis 
    Cancer     Decubitus ulcer 
    Congestive Heart Failure   Difficulty swallowing 
    Chronic Lung Disease     or refusal to eat 
    Sepsis  
    Cirrhosis 
    HIV/AIDS 
 
 
           73 
Cardiac     Pulmonary 
   Ejection Fraction < 20%   Dyspnea at rest 
   Symptoms despite diuretic/vasodilator  FEV1 < 30% 
   Not transplant candidate   Frequent ER or hospital admits for  
   History of cardiac arrest    pulmonary infection or respiratory distress 
   History of syncope    SaO2 < 88% on O2 
   Systolic BP < 120    Cor pulmonale 
   CVA of cardiac origin    pCO2 > 50 
        Resting tachycardia > 120 
   One or more comorbid conditions:  One or more comorbid conditions:  
    Cancer     Cancer     
    Chronic Lung Disease    Congestive Heart Failure  
    Sepsis      Sepsis 
    Cirrhosis     Cirrhosis 
    HIV/AIDS     HIV/AIDS 
 
Liver     Stroke/CVA 
   End-stage cirrhosis    Coma at onset 
   Not transplant candidate   Coma > 3 days duration 
   Protime > 5 sec and albumin <2.5  Limb paralysis 
   Ascites unresponsive to treatment  Urinary/fecal incontinence 
   Hepatorenal syndrome   Impaired sitting balance 
   Hepatic encephalopathy   KPS < 50% 
   SBP     Recurrent aspiration 
   Recurrent variceal bleed   Age > 70 
   One or more comorbid conditions:  One or more comorbid conditions:  
    Cancer     Cancer     
    CHF     CHF 
    Chronic Lung Disease    Chronic Lung Disease   
    Sepsis      Sepsis 
    Cirrhosis     Cirrhosis 
    HIV/AIDS     HIV/AIDS 
 
 
HIV/AIDS    Neuromuscular 
   Persistent decline in function   Diminished respiratory function 
   Chronic diarrhea     Chosen not to receive BiPAP/MV 
   Decision to stop treatment   Difficulty swallowing 
   CNS lymphoma    Diminished functional status 
   Systemic lymphoma    Incontinence 
   Dilated cardiomyopathy   One or more comorbid conditions:   
   CD4 < 25 with disease progression   Cancer 
   Viral load > 100,000     CHF 
         Chronic Lung Disease    
          Sepsis 
         Cirrhosis 
         HIV/AIDS 
 
Caring Criteria Components [or combination(s) of components] predicting 1-year mortality probability 
of 0.49 or greater (49 % or greater): 
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Caring Criteria Components [or combination(s) of components] predicting  
1-year mortality probability of 0.49 or greater (49 % or greater): 
 
Age < 55: A and/or R Plus C and/or I and or NG 
 
 
Age 55-65: A and/or R Plus C and/or I  
  NG 
 
Age 66-75: A and/or R Plus C and/or I  
  NG 
 
Age > 75: A plus R 
  C 
  I 
  NG 
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PCN Prognostic Assessment 
Non-Disease Specific 
Charlson Comorbidity Index  (CCI) 
 
Score = total points 
Comorbidity component (# points) 
Myocardial infarction    (1) 
Congestive heart failure    (1) 
Peripheral vascular disease   (1) 
Cerebrovascular disease    (1) 
Dementia      (1) 
COPD       (1) 
Connective tissue disease   (1) 
Peptic ulcer disease    (1) 
Diabetes mellitus-uncomplicated  (1) 
Diabetes mellitus-end organ damage (2) 
Chronic kidney disease-moderate to severe (2) 
Hemiplegia      (2) 
Leukemia      (2) 
Malignant lymphoma    (2) 
Solid tumor      (2) 
 Solid tumor-metastatic   (6) 
Liver disease-mild     (1) 
 Liver disease-moderate to severe (3) 
AIDS       (6) 
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PCN Prognostic Assessment 
Non-Disease Specific 
Population: Newly Admitted Nursing Home Residents 
Mortality Risk Index Score (MRIS) 
MRIS variables     MRIS Points 
Presence of cancer    2.43 
Shortness of breath    2.15 
CHF      1.66 
Bedbound     1.99 
Male      1.42 
Unstable conditions    1.59 
<75% of food eaten    1.75 
Low functional ability score   1.77 
Swallowing problem    1.41 
Bowel incontinence    1.44 
BMI < 23 
 
Correlation of MRIS points with 1-year mortality risk % 
  0-1    11.4 
  2-3    20.2 
4-5    32.3 
  6-7    44.5 
  8-9    55.9 
  10-11    69.0 
  12-13    81.7 
  14-15    87.6 
  16-17    95.4 
  18-19    100 
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PCN Prognosis Assessment 
Non-Disease Specific 
Population: Hospital Palliative Care Consults 
 
Palliative Prognostic Score (PaP): 30-day survival probability 
 
PaP Variables     PaP points 
Dyspnea Yes    1 
  No    0 
Anorexia Yes    1.5 
  No    0 
KPS  30 or greater   0 
  Less than 30   2.5 
Total WBC 4.8-8.4    0 
  8.5-11    0.5 
  > 11    1.5 
Lymphocyte% 20-40    0 
  12-19.9    1.0 
  <11.9    2.5 
Clinician 
 Prediction 
#Weeks  
     Survival >12    0 
  11-12    2 
  7-10    2.5 
  5-6    4.5 
  3-4    6 
  1-2    8.5 
 
Total Possible     17.5 points 
 
 
Correlation of Points score with 30 day mortality % 
 
 0-5.5  >70% 
 5.6-11.0 30%-70% 
 11.1-17.5 <30% 
78 
 
PCN Prognostic Assessment 
Non-Disease Specific 
Population: Community Hospital (age 70 or greater, excluding ICU, LOS less than 2 days) 
Prognostic Index 1-yr Mortality Older Adults (PIMOA) 
PIMOA variables    PIMOA points 
Male      1 
ADL Dependence at discharge 
 1-4 ADLs    2 
 All ADLs    5 
CHF      2 
Cancer-localized    3 
Cancer-metastatic    8 
Admission creatinine 
 3.0 or greater    2 
Admission albumin 
 3.0-3.4     1 
 <3.0     2 
 
Correlation of total points with 1-year mortality risk % 
  0-1    4 
  2-3    19 
  4-6    34 
  >6    63 
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PCN Prognosis PPS 
 
Prognostic Assessment PPS (Palliative Performance Scale) 
 
Population: Non-disease specific 
  Community Palliative Program Consults 
   Acute care 
   LTC 
   In-patient hospice unit 
 
 Survival Rate % 
    
 #days: 1 3 5 7 14 30 45 60 90 180 365 
PPS(%) 
  
80  100 100 100 100 100 100 81 75 46 35 10 
 
70  100 97 96 95 94 82 76 68 57 36 12 
 
60  100 100 100 98 91 65 52 41 25 10 7 
 
50  100 97 94 91 76 57 41 33 14 4 0 
 
40  98 97 96 88 73 50 36 27 16 8 1 
 
30  97 87 71 63 42 23 22 17 11 2 0 
 
20  92 72 53 42 19 8 6 5 4 0 0 
 
10  52 33 19 13 5 0 0 0 0 0 0 
 
 
 
JPSM. 2009;37(6):965 
 
 
 
 
 
 
PCN Prognosis Assessment PALIAR       80 
6 month mortality % for patients with Advanced Chronic Medical Conditions: 
 Chronic heart failure, NYHA III-IV 
 Chronic lung failure, dyspnea stage 3+, sat <90% RA or chronic O2 
 Chronic renal failure, GFR<30, creat 3 or greater 
 Chronic liver failure, Child-Pugh > 7 
 Chronic neurologic disease with cognitive impairment (18 or less MMSE) or  
  functional impairment (Barthel Index < 60) 
 
 
Characteristics     PALIAR score 
 
85 years old or more    3 
Anorexia     3.5 
Dyspnea at rest     3.5 
Pressure ulcer(s)    3 
Serum albumin < 2.5    4 
ECOG 3 or more    4 
 
0 – 21 points 
 
 
 
Correlation with observed mortality(% in 6 months): 
 
Points     % mortality 6 months 
0   21 
3   25 
3.5   37 
4   39 
6-6.5   43 
7-7.5   47 
8-10.5   65 
11-21   67 
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PCN Prognostic Assessment 
Non-Disease Specific 
Parameters of Prognosis Time Estimate 
 
Hours to Days    less than 4 days 
Days to Weeks    4 to 30 days 
Weeks to Months   31 to 180 days 
Months to Years   more than 181 days 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCN Chemotherapy Response and Survival Data      82 
Patients with diagnosis of solid organ cancer who were in good enough health to participate in clinical 
trial > ambulatory and good functional status) 
 
   Response rate % Median Duration of Response  Median Survival 
   ______________   (months)          (months) 
 
Breast   25-55    8-12   24-36 
 
Lung (Nonsmall Cell)  
 Squamous 24-36    4-6   6-11 
 Nonsquamous 20-25    4-6   10-12 
 
Esophagus  30-50    4-6   6-9 
 
Gastro-Esophageal 40-60    6-8   9-12 
 Junction 
 
Gastric 
 HER2 negative 20-40    4-7   6-11 
 HER2 positive ~50    6-7   12-14 
 
Pancreas  20-32    4-6   8-11 
 
Liver 
 Hepatocellular 25-40    2-5 
  HCC 
 Nonhepatitis C        6-10 
   related HCC 
 Hepatitis C         14 
   related HCC 
 
Biliary-Cholangiocarcinoma  20-35   4-8   9-14 
 
Colon   30-45    8-10   16-21 
 
Melanoma  15-40    4-14   6-15 
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Prognosis Assessment: Disease specific, all cancers 
Palliative Prognostic Index (PPI) 
Population: cancer patients in palliative care unit 
 
Variable      Points 
PPS 
 10-20      4.0 
 30-50      2.5 
 60 or greater     0 
 
Oral Intake 
 Severely reduced    2.5 
  (less than mouthfuls) 
 Moderately reduced    1.0 
 Normal      0 
 
Edema 
 Present      1.0 
 Absent      0 
 
Dyspnea at rest 
 Present      3.5 
 Absent      0 
 
Delirium 
 Present      4.0 
 Absent      0 
 
Risk Groups: A(PPI 2 or less)  B(PPI more than 2 up to 4) C(more than 4) 
 
Expected Survival: PPI more than 6 less than 3 weeks 
   PPI more than 4 less than 6 weeks 
 
 
 
 
 
 
KPS Mortality Prediction        84 
Patient population: Hospice patients with cancer 
 
Predicted Survival in Days 
 
 KPS(%)  10-20   30-40       50 or greater 
  50% Dead  90% Dead  50% Dead  90% Dead 50% Dead  90% Dead 
# Symptoms         
0  53            232  115     450       172         450 
1  38-46        168-199 83-98 362-428 125-191        450   
2  29-38        128-165 63-82 275-356 95-123          413-450 
3  23-30        101-131 50-62 218-270 75-93          328-406 
4  19-23          10-95 41-49 181-215 62-74          272-322 
5  16            72 36 156  54           234 
 
Symptoms: 
 Dry mouth 
 Dyspnea 
 Anorexia or difficulty eating 
 Trouble swallowing 
 Weight loss 
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Cancer Presentations with a Median Survival of Six Months or Less 
Breast  
 Any metastatic breast carcinoma with one or more of the following: 
   KPS < 60, ECOG >2 
   Ca++ > 11.2 
   Spinal cord compression with decreased ability to walk 
   C-reactive protein > 10 and albumin < 3.5 
   Peritoneal or leptomeningeal metastases 
  
 Any metastatic breast carcinoma with three or more of the following: 
   KPS < 80, ECOG > 2 
   LDH > 500 
   Any liver metastasis 
   2 different sites of metastasis 
   Disease free interval from presentation to metastases < 24 months 
   Recurrent or refractory disease after initial chemoRx 
   ER - , PR – 
 
 Metastatic breast carcinoma and brain metastases with one or more of the following: 
  KPS < 80, ECOG > 2 
  2 or more brain metastases plus extracranial metastases 
  ER -, PR – 
 
Brain  (Glioblastoma) 
with one or more of the following: 
  KPS < 70, ECOG > 2 
  Suboptimal resection or unresectable 
  Progressive or refractory despite initial treatment 
   
with two or more of the following: 
  KPS < 90, ECOG > 1 
  Age > 55 
  Recurrent disease after initial treatment 
Lesion in critical hemispheric region 
  Tumor volume > 50cm3 before resection 
  Hgb < 12 
  Platelet count > upper limit of normal 
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Colorectal  
 
 Metastatic colorectal carcinoma with one or more of the following: 
   KPS < 70, ECOG 2 or greater 
   Age > 75 
   Brain metastases with KPS < 80, age > 70 
 
 Metastatic colorectal carcinoma with two or more of the following: 
   KPS < 90, ECOG 1 or greater 
   Peritoneal carcinomatosis 
More than 2 metastatic sites 
Malignant ascites 
Refractory disease after chemoRx 
 
 
Esophageal/Gastric 
 
 Locally advanced or metastatic esophageal/gastric with one or more of the following: 
   KPS < 80, ECOG > 1 
   Recurrent or refractory disease with disease-free interval < 6 months 
 
 Locally advanced or metastatic esophageal/gastric with two or more of the following:  
   KPS < 90, ECOG 1 or greater 
   Liver or peritoneal metastases 
   Alkaline phosphatase > 100 
   LDH > 200 
   Hgb < 11 
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Hepatobiliary/Pancreatic Carcinoma 
 Locally advanced or metastatic biliary tract or pancreatic with one or more of the following: 
   KPS < 90, ECOG 1 or greater 
   Total bilirubin > 10 
   Recurrent or refractory after initial chemoRx 
   Liver, peritoneal, or distant metastases 
   Portal vein thrombosis 
   Albumin < 3.5 
   LDH > 500 
   Episode of DVT or PE 
   Malignant ascites 
 
     
 
 
 Any hepatocellular carcinoma with one or more of the following: 
   KPS < 60, ECOG > 2 
   Tumor diameter > 10 cm 
   Any brain metastasis 
 
  
Unresectable  locally advanced or metastatic hepatocellular carcinoma with two or more of the 
following: 
  KPS < 90, ECOG 1 or greater 
  Extrahepatic metastases 
  Symptomatic cirrhosis: 
   Jaundice 
   Ascites 
   Fatigue 
   bleeding 
  AFP > 400 
  Portal vein thrombosis 
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Head and Neck Squamous Cell 
 
Recurrent, refractory, or metastatic head and neck squamous cell carcinoma with one or more 
of the following: 
  KPS < 90, ECOG 1 or greater 
  Recurrence of disease with any metastasis 
   Greater than 10% weight loss 
   Muscle invasion or residual tumor at primary site 
   Pretreatment Hgb < 11 
   Ca++ > 11.2 
 
      
 
Thyroid 
 Anaplastic thyroid cancer with one or more of the following: 
   Extracapsular extension or metastases 
   Unresectable disease or incomplete resection 
 
      
 
Melanoma 
 Advanced or metastatic melanoma with one or more of the following: 
   KPS < 80, ECOG 2 or greater 
   LDH x 2 upper limit of normal 
   Ca++ > 11.2 
   Metastases to brain or spine 
   Metastases to liver and one other site 
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NSCLC 
 Any locally advanced or metastatic NSCLC with one or more of the following: 
   KPS < 70, ECOG > 2 
   Weight loss of 5% or albumin < 3 
   Liver metastases 
   Bone metastases 
   CNS metastases with symptoms, age > 65 
   Pericardial involvement 
   Pleural effusion with evidence of distant metastases 
   Hgb < 12 
   Ca > 11 
    
    
   
(SCLC) 
 Extensive Disease: median survival 6-12 months with Rx, 4 months without Rx 
    
Female Genital 
Locally advanced or metastatic ovarian/endometrial/cervical with regional or distal spread and 
one or more of the following: 
  KPS < 60, ECOG > 2 
  Ca++ > 11.2 
  2 or more brain metastases 
  Bowel obstruction without successful repair or urinary tract obstruction 
  Unresectable disease 
 
Locally advanced or metastatic ovarian/endometrial/cervical with regional or distal spread and 
two or more of the following: 
  KPS < 80, ECOG > 1 
  Recurrent or refractory disease 
  Disease-free interval < 6 months (diagnosis to recurrence) 
  Suboptimal resection with bulky residual disease 
  Weight loss > 5% 
  Extra-abdominal metastases 
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Male Genital 
 Hormone-refractory metastatic prostate cancer with one or more of the following: 
   KPS < 60, ECOG > 2 
   Hgb < 10 
   Spinal cord compression with decreased ability to walk 
 
Bladder and Renal Cell 
 Locally advanced or metastatic bladder or renal cell cancer with one or more of the following: 
   KPS < 70, ECOG > 2 
   Greater than 2 brain metastases 
   Ca++ > 11.2 
 
 Locally advanced or metastatic bladder or renal cell cancer with three or more of the following: 
   KPS < 80, ECOG 2 or greater 
   Hgb < 11.5 
   LDH > 300 
Disease-free interval < 1 year 
   Visceral metastases 
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Solid Cancers in general 
 Any locally advanced or metastatic solid cancer with one or more of the following: 
   KPS < 60, ECOG > 2 
   Ca++ > 11.2 
   Episode of DVT or PE 
   Any brain metastasis with KPS < 70 
   More than 2 brain metastases and extracranial metastasis 
   Spinal cord compression with decreased ability to walk 
   Malignant pericardial effusion 
   
Unknown Primary 
Any metastatic adenocarcinoma or undifferentiated carcinoma of unknown primary with one or 
more of the following: 
  KPS < 80, ECOG > 1 
  Hepatic, bone, or adrenal metastases 
  Recurrence of disease after chemoRx 
  Albumin < 3.5 or weight loss of  > 10% in 6 months 
 
Acute Leukemia 
 Acute Lymphoblastic or myeloid leukemia with one or more of the following: 
   Age > 70 
   Extramedullary disease involving Central Nervous System 
   Refractory to 2 or more courses of chemoRx 
   Recurrence with disease-free interval of < 14 months 
 
 Acute Lymphoblastic or myeloid leukemia with two or more of the following: 
   Age > 60 
   KPS < 80, ECOG 2 or greater 
   Central Nervous System involvement 
   Evidence of hemorrhage or infection 
   WBC  > 25 
   LDH > 500 
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Chronic Leukemia 
 Chronic myeloid leukemia in blast transformation with one or more of the following: 
   Age > 50 with predominant myeloid origin 
   Myeloid blast transformation with WBC > 50, plt < 100, or Hgb <10 
   Greater than 50% blasts in peripheral blood 
Chronic lymphocytic leukemia with one or more of the following: 
   Refractory to initial chemoRx 
   Recurrent disease after 2 or more courses of chemoRx 
 
    
Lymphoma/Multiple Myeloma 
 Non-Hodgkins lymphoma or multiple myeloma with one or more of the following: 
   Secondary extranodal or extramedullary involvement of CNS 
   Primary CNS lymphoma related to HIV 
 
Aggressive non-Hodgkins lymphoma or multiple myeloma that is refractory or recurrent after 
initial treatment – with 2 or more of the following: 
  KPS < 70, ECOG 2 or greater 
  Age > 65 
  LDH above normal 
 albumin < 3 
multiple myeloma with plt < 80 
multiple myeloma with serum creatinine 2 or greater 
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Non-Cancer Presentations with a Median Survival of Six Months or Less 
Heart Failure 
Hospitalization for moderate to severe symptomatic heart failure (HF), NYHA (New York Heart 
Association) Class III or IV with three or more of the following: 
  Age > 70 
  Left Ventricular Ejection Fraction (LVEF) 20% or less 
  Beta-type Natriuretic Peptide (BNP) > 950 
  Cardiac troponin I > 0.4 
  C-reactive protein > 3.5 
  4th hospitalization for CHF or repeat hospitalization within 2 months 
  Dependency of 3 or more ADL (activities of daily living) or need for home care 
  Weight loss of 2.3 kg or greater in 2 months or albumin< 2.5 
  History of:  
   Cardiogenic shock 
   Ventricular or supraventricular arrhythmia 
   Cardiac arrest 
   Cardiopulmonary resuscitation or 
   Mechanical ventilation 
  Systolic blood pressure < 110 
  Creatinine > 2 or BUN > 40 
  Sodium < 135 
  Cardiovascular disease: 
   Ischemic cerebrovascular disease or 
   Peripheral vascular disease 
  Other comorbid illness: 
   Diabetes Mellitus 
   Dementia 
   COPD 
   Cirrhosis 
   Cancer 
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Dementia 
 Advanced dementia with dependency in all activities of daily living, bedbound status, 
urinary and bowel incontinence, decreased ability to communicate verbally, AND admission to a 
hospital or skilled nursing facility with one or more of the following: 
  BMI < 18.5, decreased oral intake, or significant weight loss 
  Presence of at least one pressure ulcer 
  Evidence of at least one comorbid illness 
  Male sex and age > 90 
  Placement of a feeding tube due to inability to eat or history of aspiration 
 
Geriatric Failure-to-Thrive 
Age > 75, albumin < 3.5, dependency in 2 or more activities of daily living, AND 
admission to a hospital or skilled nursing facility with one or more of the following: 
 Dependency in all activities of daily living with malnutrition 
  (weight loss >10% or albumin < 3) 
 Evidence of heart failure 
 Creatinine > 3 
 Evidence of delirium during hospitalization 
  
 
End-Stage Renal Disease (ESRD) 
 ESRD on dialysis with age > 70 and 2 or more of the following: 
   KPS < 50 
   Significant comorbid condition such as  
    Coronary artery disease 
    Peripheral vascular disease 
    Heart failure 
    Cancer 
   Malnutrition 
    BMI < 19.5 or albumin < 2.2 
   Residence in a skilled nursing facility 
   Admission to an intensive care unit for an acute illness 
   Hip fracture with inability to ambulate 
 
 ESRD without dialysis with age > 70 and 1 or more of the following: 
Dialysis withheld due to decreased performance status and significant 
comorbidity 
 
Dialysis withdrawn due to advanced age, functional dependence, and 
comorbidity 
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Cirrhosis 
 Decompensated hepatic cirrhosis and 1 or more of the following: 
   Child-Pugh 12 or greater 
   MELD 21 or greater 
 
Decompensated hepatic cirrhosis with hospitalization for an acute illness related to liver disease 
and 1 or more of the following: 
   Child-Pugh 10 or greater 
   MELD 18 or greater 
   Child-Pugh 9 or greater AND dependency in 3 or more ADL AND 
    malnutrition (significant weight loss and albumin < 2.5 
   Hospitalization in an intensive care unit related to severe decompensation of  
    liver disease, with hypotension requiring the use of vasopressors,  
    creatinine > 1.5,  OR evidence of jaundice 
   Evidence of hepatopulmonary syndrome or rapidly progressive hepatorenal 
    syndrome 
 
     
Chronic Obstructive Pulmonary Disease (COPD) 
 Hospitalization for a severe COPD exacerbation with hypoxemia (paO2 < 55), 
 hypercapnia (pCO2 > 50), dependence on supplemental O2, and 3 or more of the following: 
   Age > 70 
Evidence of cor pulmonale 
   Repeat hospitalization within 2 months 
   History of intubation/mechanical ventilation 
   KPS < 60 
   Need for home care after discharge 
   Malnutrition  (weight loss > 2.3 kg, albumin < 2.5, or BMI < 18 
   Creatinine > 2 
 
 
 
 
 
 
 
 
 
 
 
PCN Chronic Obstructive Pulmonary Disease (COPD-CODEX)    96 
Mortality Prediction at 3 months and 1 year 
 
Comorbidity : Charlson Index 
   0-4   0 points 
   5-7   1 point 
   8 or greater  2 points 
Obstruction: FEV1% 
   65 or greater  0 points 
   50-64   1 point 
   36-49   2 points 
   35 or less  3 points 
Dyspnea: mMRC = modified medical research council dyspnea scale 
   0-1   0 points 
   2   1 point 
   3   2 points 
   4   3 points 
EXacerbation: exacerbations during the previous year (requiring ED visit and/or hospitalization) 
0 0 points 
1-2                                      1 point 
  3 or more  2 points 
 
Score 1-10 
    
 
    
 
 
Score   Predicted 3 month mortality (%)  Predicted 1 year mortality (%) 
 
0   0      0 
1   0      2 
2   0      5 
3   2      10 
4   5      15  
5   5      18 
6   8      20 
7   10      25 
8   15      30 
9   18      35 
10   20      50    
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Mortality Prediction at 4 years 
 
Variable     BODE Index points 
 
Body Mass Index (BMI) 
 More than 21    0 
 21 or less    1 
Obstruction 
 FEV1% - 65 or greater   0 
 FEV1%   50-64    1 
 FEV1%   36-49    2 
 FEV1%   35 or less   3 
Dyspnea 
 mMRC 0-1    0 
 mMRC 2    1 
 mMRC 3    2 
  mMRC 4    3 
Exercise 
 6-minute Walk Test (meters) 
  350 or more   0 
  250-349   1 
  150-249   2 
  149 or less   3 
 
Score 1-10 
 
 
 
 
Approximate 4-year mortality (%) 
 
BODE Score  4-year mortality (%) 
 
0-2   20 
3-4   33 
5-6   43 
7-10   82 
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Prognostic Index: Liver Disease 
 
Child-Pugh Score 
 Class A  5-6 points 
 Class B  7-9 points 
 Class C  10-15 points 
 
Variable      Points 
 
Serum bilirubin 
  <2     1 
  2-3     2 
  >3     3 
 
Serum albumin 
  3.5 or greater    1 
  3-3.5     2 
  Less than 3    3 
 
Prothrombin time (INR) 
  Less than 1.7    1 
  1.7-2.3     2 
  2.3 or greater    3 
 
Ascites 
  None     1 
  Slight     2 
  Moderate     3 
 
Encephalopathy 
  None     1 
  Minimal    2 
  Advanced    3 
   
 
 
 
 
 
 
PCN Heart Failure Risk Scoring System (HFRSS)      99 
 
Disease-Specific, Non-Cancer Heart Failure 
Community and Teaching Hospitals within 24 hours of admission (excludes > 105 years old and 
non-residents) 
 
Survival/Mortality Prediction at 30 days and 1-year 
 
Start with age in years as initial score:  30 day   1-year 
 Respiratory Rate    + rate (breaths/min) + rate (breaths/min) 
 Systolic BP 
  180 or more    - 60   - 50 
  160-179    - 55   - 45 
  140-159    - 50   - 40 
  120-139    - 45   - 35 
  100-119    - 40   - 30 
  90-99     - 35   - 25 
  Less than 90    - 30   - 20 
 Blood Urea Nitrogen (max 60 mg/dl)  + level in mg/dl + level in mg/dl 
 Serum Sodium less than 136 meq/l  + 10   + 10 
 Cerebrovascular Disease   + 10   + 10 
 Dementia     + 20   + 15 
 Chronic Obstructive Pulmonary Disease + 10   + 10 
 Cirrhosis     + 25   + 35 
 Cancer      + 15   + 15 
Hemoglobin less than 10 g/dl   NA   + 10 
 
 
Risk Category  HFRSS Score  30 day mortality (%)  1-year mortality (%) 
 
Very Low  less than 60  0.5    5-8 
Low   61-90   3-4    12-15 
Intermediate  91-120   12-15    30 
High   121-150  30    55-60 
Very High  more than 150 50-60    75 
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Prognosis Assessment: PLAN Clinical Prediction Rule 
Population:  hospital admission acute ischemic stroke without thrombolysis 
    
Variable      Points 
Preadmission medical comorbidities 
 ADL dependence    1.5 
 Cancer      1.5 
 CHF      1.0 
 Atrial Fibrillation    1.0 
 
Level of consciousness 
 Reduced     5.0 
 
Age       One point per decade (max = 10) 
 
Neurologic deficit 
 Arm weakness     2.0 
 Leg weakness     2.0 
 Neglect or aphasia    1.0 
______________________________________________________________________________ 
Correlation of PLAN Score to   30 day and  1 year   m-R* of 5 or 6 ( %) 
mortality % 
  Less than 6  0.7  2.1  0.9    
   6  1.9  4.8  1.2   
   7  1.4  4.5  1.3 
   8  2.1  6.4  2.5 
   9  4.4  13.1  4.3 
   10  4.4  16.2  6.0 
   11  7.6  21.7  9.8 
   12  10.9  26.3  14.8 
   13  15.3  32.0  20.3 
   14  21.7  42.2  30.7 
   15  29.3  46.0  35.8 
   16  35.4  57.7  43.9 
   17  42.5  63.3  54.4 
   18  50.5  74.3  65.0 
   19  61.2  73.8  73.2 
  More than 19  65.9  83.6  78.4 
 
*= modified Rankin score 
PCN Prognosis Assessment Prolonged Mechanical Ventilation (ProVent score)   101 
 
Mortality Prediction at 3 months and 1 year for patients receiving prolonged mechanical ventilation – 
measured on day #21 of mechanical ventilation 
 
One (1) point each for: 
   Age 50 years or more 
   Vasopressor 
   Platelet count 150,000 or less  
   Hemodialysis or CRRT 
 
 
Score   Observed 3 month mortality (%)  Observed 1 year mortality (%) 
 
0   12      15 
1   29      42 
2   77      88 
3   91      95 
4   95      100    
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCN Intracranial Hemorrhage (ICH Score)      102 
 
Components    Points 
Glasgow Coma Scale (GCS) 
 3-4    2 
 5-12    1 
 13-15    0 
ICH volume, cm3 
 30 or more   1 
 Less than 30   0 
Intra-ventricular hemorrhage 
 Yes    1 
 No    0 
Infra-tentorial origin 
 Yes    1 
 No    0 
Age, years 
 80 or more   1 
 Less than 80   0 
 
Score 0-6 
 
 
30-day mortality (%) correlated with ICH score: 
 
Score  30-day Mortality (%) 
0 0 
1 10 
2 25 
3 75 
4 95 
5 99 
6 100 
 
 
 
 
 
 
 
 
 
PCN Survival Postresuscitation – In-Hospital Cardiac Arrest (CASPRI)   103 
Predictor    Points 
Age, years 
 59 or less   0 
 60-69    1 
 70-79    2 
 80 or older   4 
Initial Rhythm VF/VT 
 Time to initial defibrillation 
  3 minutes or less 0 
  4-5 minutes  2 
  5 minutes or more 3 
Initial Rhythm PEA   6 
Initial Rhythm Asystole   7 
Prearrest CPC score 
1 0 
2 2 
3 or more   9 
Location of arrest 
 Telemetry unit   0 
 Intensive Care Unit  1 
 Non-monitored unit  3 
Duration of Resuscitation (minutes) 
 4 or less   0 
 5-9    3 
 10-14    5 
 15-19    6 
 20-24    6 
 25-29    6 
 30 or more   8 
Factors present prior to arrest 
 Mechanical ventilation  3 
 Renal insufficiency  2 
 Hepatic insufficiency  4 
 Sepsis    3 
 Cancer    4 
 Hypotension   3 
Predictor Points correlated with likelihood (mean survival %) of survival to hospital discharge 
 0-4 82.6  20-24 12.3    
 5-9 66.6  25-29 5.2  35 points or more = 0% survival to discharge 
 10-14 42.0  30-34 2.1 
 15-19 23.1  >34 
PCN Cerebral Performance Category after Resuscitation Attempt (GO-FAR)   104 
GO-FAR: Good Outcome Following Attempted Resuscitation 
 
Variable       GO-FAR Score 
Neurologically intact or with minimal deficits at admission - 15 
 
Major trauma       10 
Acute stroke       8 
Metastatic or hematologic cancer    7 
Documented bloodstream infection    7 
Medical noncardiac diagnosis     7 
Hepatic insufficiency      6 
 Bilirubin >2 mg/dl 
 AST > 2x normal 
 Cirrhosis 
Admit from skilled nursing facility    6 
Hypotension or hypoperfusion     5 
 Mean BP < 60 
 Vasopressor 
 IABP 
Renal insufficiency or dialysis/CRRT    4 
 Serum creatinine > 2 mg/dl 
Respiratory insufficiency     4 
 Intubation/mechanical ventilation 
 NIPPV 
 PaO2/FiO2 < 300 
 PaCO2 > 50 mmHg 
 PaO2 < 60 
Pneumonia       1 
Age 
 70-74       2 
 75-79       5 
 80-84       6 
 85 or older      11 
 
GO-FAR Score correlated with % of survivors with CPC of 1  (chances for “good outcome”) 
 24 or more  0.8 (very low – less than 1%) 
 14-23   2.0 (low – 1-3%) 
 -5 to 13   9.2 (average – 3 -15%) 
 -15 to -6  27.8 (above average – more than 15%) 
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General End-Stage Disease Guidelines 
 
Changes in clinical variables apply to patients whose decline is not considered reversible 
Documented decline in functional status (both should be met) 
1. Assistance needed with at least 2 ADLs (toilet, feed, dress, groom, walk, bathe) 
2. Decline in PPS to less than 70%  
 
Decline in nutritional status 
 Unintentional progressive weight loss (10% over 6 months) 
 Serum albumin < 2.5 gm/dl 
 Dysphagia leading to recurrent aspiration and/or inadequate intake 
 
Increased ED visits, physician visits, or hospitalizations related to primary hospice diagnosis 
 
Multiple co-morbidities 
 
Goal for palliative care  
 
 
 
Adult “failure to thrive” 
 
PPS < 50% 
BMI < 22 
 
Declining enteral or parenteral nutrition support or has not responded to such nutritional 
support, despite adequate caloric intake 
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Dementia 
 
The patient has dementia which has progressed to: 
 FAST stage 7 or beyond 
 Unable to ambulate without assistance 
 Unable to dress without assistance 
 Unable to bathe without assistance 
 Urinary and fecal incontinence, intermittent or constant 
 No meaningful verbal communication 
  Stereotypical phrases only 
  Ability to speak is limited to six or fewer intelligible words 
 
AND 
 
The patient must have had one of the following within the past 12 months 
 Aspiration pneumonia 
 Pyelonephritis or other upper urinary tract infection 
 Septic episode 
 Decubitus ulcers, multiple, stage 3-4 
 Fever, recurrent after antibiotics 
 Inability to maintain sufficient fluid and calorie intake 
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Liver Disease 
 
The patient has end-stage liver disease demonstrated by: 
 Prothrombin time >5 sec – OR - INR > 1.5 – AND - serum albumin < 2.5 gm/dl 
AND: 
One or more of the following: 
 Refractory ascites 
 History of SBP 
 Hepatorenal syndrome 
 Refractory hepatic encephalopathy 
 History of recurrent variceal bleeding 
 
Additional supporting documentation: 
 Progressive malnutrition 
 Muscle wasting with reduced strength and endurance 
 Continued active alcoholism (>80 gm alcohol/day) 
 Hepatocellular carcinoma 
 Hepatitis B positivity 
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Neurologic Disease 
 ALS 
 Parkinsons 
 Muscular Dystrophy 
 Myasthenia Gravis 
 Multiple Sclerosis 
 Neuromuscular Disease 
 
Meet at least one of the following criteria: 
 
1. Critically impaired breathing capacity – all of following: 
a. Dyspnea at rest 
b. Vital capacity < 30% 
c. Requires oxygen at rest 
d. Declines mechanical ventilation 
 
2. Rapid disease progression: 
a. Independent ambulation to wheelchair or bed-bound status 
b. Normal to barely intelligible or unintelligible speech 
c. Normal to pureed diet 
d. Independence in most ADLs to needing major assistance in all ADLs 
 
AND 
 
Critical nutritional impairment – all of the following in the last 12 months: 
a. Oral intake of nutrients and fluids insufficient to sustain life 
b. Continuing weight loss 
c. Dehydration or hypovolemia 
d. Absence of artificial feeding methods 
 
3. Rapid disease progression: 
a. Independent ambulation to wheelchair or bed-bound status 
b. Normal to barely intelligible or unintelligible speech 
c. Normal to pureed diet 
d. Independence in most ADLs to needing major assistance in all ADLs 
 
AND 
Life threatening complications – one or more of the following in the last 12 months: 
a. Recurrent aspiration pneumonia 
b. Pyelonephritis 
c. Sepsis or recurrent fever 
d. Stage 3 or 4 decubitus ulcer(s) 
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Heart Disease/Cardiovascular 
 
The patient has 1 and either 2 or 3: 
 
1. CHF with NYHA class IV symptoms and both: 
a. Significant symptoms at rest 
b. Inability to carry out even minimal physical activity without dyspnea or angina 
 
2. Patient is optimally treated with diuretics and vasodilators including ACEI 
 
3. The patient has angina pectoris at rest, resistant to medical therapy, and is either not a 
candidate  for/or has declined invasive procedures. 
 
 
Supporting documentation: 
 EF < 20% 
 Treatment resistant dysrhythmias 
 Cardiac-related syncope 
 Stroke related to cardiac embolism 
 History of CPR 
 Concomitant HIV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCN Hospice Diagnosis/Category Criteria Examples      110 
 
 
HIV/AIDS 
 
The patient has either 1A or 1B;  AND 2 AND 3 
 
1A. CD4+ < 25 
1B. viral load > 100,000 
2. At least one of the following: 
  CNS lymphoma 
  Untreated or refractory wasting (loss of > 33% lean body mass) 
  MAC bacteremia 
  PML 
  Systemic lymphoma 
  Visceral KS 
  Renal failure, no HD 
  Cryptosporidium infection 
  Refractory toxoplasmosis 
 
3. PPS < 50% 
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Pulmonary Disease 
The patient has: 
Disabling dyspnea at rest or with minimal exertion and little or no response to bronchodilators, resulting 
in decreased functional capacity, fatigue, cough,  AND 
 
Progression of end-stage pulmonary disease, as evidenced by prior increasing visits to the emergency 
department or prior hospitalizations for pulmonary infections and/or respiratory failure, AND 
 
Room air findings of hypoxemia, as evidenced by pO2 < 55 mmHg and oxygen saturation < 88% or 
hypercapnia as evidenced by pCO2 > 50 mmHg 
 
Cor pulmonale and right heart failure secondary to pulmonary disease (not secondary to left heart 
disease or valvulopathy) 
 
Unintentional progressive weight loss greater than 10% of body weight over the preceding six months 
 
Resting tachycardia > 100 bpm 
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Renal Failure 
 
A patient has: 
Acute renal failure OR 
Chronic renal failure (ESRD) AND 
 
The patient is not undergoing dialysis AND 
Creatinine clearance < 10 cc/min OR 
Serum creatinine > 8 mg/dl (6 for diabetics) 
 
Supporting documentation: 
Mechanical ventilation 
Malignancy 
Chronic lung disease 
Advanced cardiac disease 
Advanced liver disease 
Sepsis 
Immunosuppression/AIDS 
Albumin < 3.5 gm/dl 
Cachexia 
Platelet count < 25,000 
Disseminated Intravascular Coagulation (DIC) 
Gastrointestinal bleeding 
Uremia 
Oliguria (<400 cc/day) 
Intractable hyperkalemia (>7.0) not responsive to treatment 
Uremic pericarditis 
Hepatorenal syndrome 
Intractable fluid overload 
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Stroke and Coma 
Acute hemorrhagic or ischemic stroke  
Poor functional status (PPS < 50 %)  AND 
Poor nutritional status with inability to maintain sufficient fluid and calorie intake as evidenced by one 
or more of the following: 
       10% or more weight loss in past 6 months 
    7.5% or more weight loss in past 3 months 
    Serum albumin < 2.5 gm/dl 
    Current history of pulmonary aspiration without effective response 
     to speech therapy interventions to improve dysphagia 
     and decrease aspiration events 
 
 
Supporting documentation: 
Coma or persistent vegetative state secondary to stroke, beyond 3 days duration 
Coma or severe obtundation, secondary to post-anoxic stroke 
 accompanied by severe myoclonus, persisting beyond 3 days after the anoxic event 
Chronic phase of hemorrhagic or ischemic stroke evidenced by: 
 Post stroke dementia, FAST stage 7 or beyond 
 Poor functional status with KPS %0% or less 
 
Coma (any etiology) with any 3 of the following on day three of coma: 
 Abnormal brainstem response 
 Absent verbal response 
 Absent withdrawal response to pain 
 Serum creatinine > 1.5 mg/dl 
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Cancer 
Clinical findings of malignancy with widespread, aggressive, or progressive disease 
 as evidenced by increasing symptoms, worsening lab values, and/or evidence of metastatic 
 disease 
AND 
PPS 70 % or less 
AND 
Refuses further life-prolonging therapy or continues to decline in spite of definitive therapy 
 (may receive disease-specific intervention if palliative) 
 
 
The following cancer disease categories are considered hospice appropriate due to the small probability 
that treatment would result in cure or cessation of disease: 
 
Category 3:  malignancies that are treatable but incurable when metastatic in a large percentage of 
patients, with favorable prognosis: 
 prostate, breast, CLL, CML, NHL, multiple myeloma, myelodysplastic syndrome 
 (often may be controlled for periods of time with hormonal and/or chemotherapy, may require  
 no therapy or are only treated when symptoms occur, generally have a history of having  
 received and failed one or more standard therapeutic regimens and should have symptoms  
 compatible with disease progression before considering hospice option) 
 
Category 4: malignancies that are treatable in only a small percentage of patients with less favorable 
prognosis: 
 invasive bladder, glioblastoma, gynecological carcinomas other than ovary, colorectal, gastric, 
 head and neck, esophageal, NSCLC, soft tissue sarcoma  
 (majority are adult solid tumors, presence of metastatic disease generally indicative of a  
 terminal prognosis, usually 40% or less of patients have an objective response to chemotherapy,  
 chemotherapy responses are usually not durable, impact of chemotherapy on symptoms and  
 quality of life not well documented in medical literature, as chemotherapy is of limited benefit  
 to most patients once these diseases have metastasized such patients could be offered the  
 option of hospice in lieu of chemotherapy, if chemotherapy is chosen by the patient as a  
 therapeutic option, failure of first-line therapy should prompt serious consideration of hospice) 
 
Category 5 malignancies that are virtually untreatable: 
 renal cell, pancreatic, malignant melanoma 
 (generally resistant to currently available chemotherapy, with the lack of efficacious systemic  
 therapy – patients with these diseases and have metastatic disease should be offered hospice  
 As an option) 
  
  
Syndrome of Imminent Death         115 
 
Early 
 Bed-bound 
 Loss of interest 
 Loss of ability to eat/drink 
 Increased time sleeping 
 +/- delirium 
 
Middle 
 Obtunded  
 Oral secretions (“rattle”) 
 
Late 
 Coma 
 Fever 
Aspiration 
Altered respiratory pattern 
Mottling  
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PCN EOL Management Palliative Sedation 
 
Confirm that goal of care is comfort 
Advanced terminal illness 
Suffering severe refractory physical or neuropsychiatric symptoms – or – psychosocial problems 
Order to withhold life-sustaining interventions 
Informed consent 
Document all of above, inform clinical team 
 
Specify loading dose, infusion, bolus doses 
 
Midazolam 
 0.3-0.5 mg/kg over 2-5 minutes 
 Infusion 0.02-0.1 mg/kg/hr 
 Additional boluses = hourly infusion rate 
 
Propofol 
 (central venous catheter only) 
 Start infusion 2.5-5.0 mcg/kg/min (10-20 mg/hr) 
 Bolus doses 10-20 mg q 10 min 
 
Pentobarbital  
 Loading dose 2-3 mg/kg 
 Infusion 1-2 mg/kg/hr 
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PCN SQ Dosing 
 
Drug    Bolus(mg)    Infusion(mg) 
 
Morphine Sulfate  2.5-5 q 4h    15-30/24 h 
Hydromorphone  2-5 q 4h    15/24 h 
Fentanyl   use infusion    0.150-0.300/24 h 
Midazolam   2.5 q 4h    20-40/24 h 
Haloperidol   0.5-2.5 q 6-8 h    5-25/24 h 
Phenobarbital   60 q 6-8 h    200-1000/24 h 
Metoclopramide  10 q 6 h    30-100/24 h 
Hyoscine   0.3-0.6 q 2-4 h    0.6-2.4/24 h 
Glycopyrrolate   0.2-0.4 q 4-6 h    0.6-1.2/24 h 
Octreotide   0.1-0.2 q 8 h    0.3-0.6/24 h 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DNAR          118 
 Patient Categories/Hierarchy of Decision-makers  
 
DNAR: Do-Not-Attempt-Resuscitation 
 
Basically healthy 
 20-40% survival 
 + benefit 
 
Advanced/Chronic Illness 
 5-20% survival 
 +/- benefit 
 
Imminent death 
 0% 
 0 benefit 
 
 
Hierarchy of decision-makers: 
 Capable patient 
 DPOAHC 
 Legal guardian 
 Spouse 
 Adult children 
 Parents 
 Adult sibling(s) 
 Grand-parents 
 Other  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pain Management Guidelines  (NCCN)         119 
 
1. Use a multidrug approach.  Combine opioids with nonopioids and adjuvant 
medications. 
 
2. Base administration schedule on the analgesic’s duration of effect.  Best to use 
sustained-release opioids for scheduled dosing and immediate-release opioids for 
rescue or breakthrough dosing. 
3. In opioid-naïve patients, start with low-dose, short-acting opioids and titrate for 
effect. 
 
4. Avoid meperidine (Demerol), propoxyphene (Darvon), and the mixed agonist-
antagonist opioids (eg, Stadol, Nubain, Talwin).  Do not exceed 4000 mg of 
acetaminophen (APAP) in 24 hours. 
 
 
5. Noninvasive routes preferred.  For severe pain or rapidly escalating pain, it may be 
necessary to provide IV analgesics until the pain is managed.  If oral or transdermal 
dosing is no longer practical or appropriate, continuous subQ or IV infusions are 
indicated. 
 
6. Mild pain (rating 1-3): Start with simple analgesics, APAP or NSAIDS, with adjuvant 
analgesics as appropriate. 
 
 
7. Moderate to severe pain (rating 4-10): When pain does not respond to nonopioid 
analgesics and adjuvants, consider adding an opioid.  Drugs with APAP, ASA, or 
NSAIDS in combination with opioids limit flexibility of dosing. 
 
8. Titration:  Increase by 25% to 50% for moderate pain; increase by 50% to 100% for 
severe pain.  Or calculate the average dose of breakthrough medication per day and 
add to the sustained-release medication dose (except when breakthrough is taken 
for incident pain). 
 
 
9. Breakthrough:  Scheduled dosing will maintain stable serum drug levels and provide 
consistent relief.  Patients receiving long-acting opioids or continuous parenteral 
infusions must have an order for breakthrough pain medication.  Frequent 
breakthrough dosing requires a change in the sustained-release drug dose.  Oral 
breakthrough dose is 10% to 20% of the oral 24-hour baseline dose.  Peak effect of 
immediate-release opioid is ~ 1 hour; may repeat dose every hour if patient is not 
sedated.  IV/SQ breakthrough dose is 50% to 100% of the hourly IV/SQ rate.  Peak 
effect of IV opioids is 10-15 minutes; may repeat dose every 15 minutes if patient  
120 
 
10. not sedated.  Peak effect of SQ opioids is 30 minutes; may repeat dose every 30 
minutes if patient not sedated.  Intramuscular dosing not recommended. 
 
11. When changing drug or route of administration, use equianalgesic doses.  If 
changing from one drug to another, the new drug may be more effective because of 
differences of potency or drug availability.  Start at 2/3  to 3/4 of the amount 
calculated by using equianalgesic tables.  Make sure breakthrough medication is 
available and titrate dose according to individual response. 
 
 
Manage opioid adverse effects.  Patients never become tolerant to the constipating effects of 
opioids.  Always start stimulant laxative/softener combination with opioids 
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Equianalgesic Opioid Conversion (Miscellaneous) 
Morphine Sulfate (MS) 30 mg PO = 10 mg IV (3:1) 
Hydromorphone (HM) 7.5 mg PO = 1.5 mg IV (5:1) 
Oxycodone (OX) 0.66 mg PO = MS 1 mg PO 
Fentanyl (FT) 1 mcg/hr = 2 mg Oral Morphine Equivalent (OME) 
Codeine 30 mg PO = MS 4.5 mg PO 
Tramadol 50 mg PO = MS 10 mg PO 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Converting Opioids: Point A to Point B      122 
 
M=morphine, H=hydromorphone, X=oxycodone, F=fentanyl, MET=methadone 
 O=oral, V=intravenous, T=transdermal 
 
 1:  all doses in mg unless otherwise noted 
 2:  note 100 mcg = 0.1 mg 
 3.  dose in mcg/hr 
A: Find current drug (Point A) in far left column 
B: Find desired drug (Point B) in top row 
  Intersection of A and B in table defines conversion ratio 
  Dose desired drug (B) = Dose current drug (A) x conversion ratio 
 
Calculated dose represents an estimated equianalgesic dose.  Significant individual patient 
variation should be expected.  The actual dose of the desired drug to administer should be 
adjusted for a variety of factors including but not limited to: age, pain intensity, cross-tolerance, 
and renal/hepatic dysfunction. 
 
Consider the following when adjusting the calculated (estimated) equianalgesic dose: 
 
 0% reduction:  moderate to severe pain, no side effects (sedation,    
   respiratory depression, neurotoxicity) on current     
  medication 
 25% reduction: mild to moderate pain, no side effects 
 50% reduction: mild or controlled pain, presence of side effects 
                          B: 
     →DESIRED1→ 
 
A:↓CURRENT1↓ 
MO 
(“OME”) 
MV HO HV XO FV2 FT3 
(MCG/HR) 
METO METV 
MO   
     (“OME”) 
 --- 1/3 1/4 1/20 2/3 1/300 1/2 ¼  
OME/24°< 90 
1/8 
OME/24°90-    
300 
1/12  
OME/24°>300 
 
MV 3/1  --- 3/4 1/7 2/1 1/100 3/2   
HO 4/1 4/3  --- 1/5 3/1 1/75 2/1   
HV 20/1 7/1 5/1  --- 14/1 1/15 10/1   
XO 3/2 1/2 1/3 1/14  --- 1/200 3/4   
FV 300/1 100/1 75/1 15/1 200/1    --- 150/1   
FT3    (MCG/HR) 2/1 2/3 1/2 1/10 4/3 1/150 ---   
METO 5/1          --- 1/2 
METV 13.5/1       1.3/1    --- 
PCN Guidelines for Opioid Rotation      123 
 
Select the new drug on the basis of pharmacologic features, previous experience, availability, cost 
Calculate the equianalgesic dose: 
 If switching to any opioid other than methadone of fentanyl: 
  Plan dose reduction of 25-50% (incomplete cross tolerance) 
  Select dose reduction closer to 50% if higher dose, elderly, medically frail 
 If switching to methadone: 
  Dose reduction is 50-75%, rarely converting to methadone at dose higher than 100 mg/day 
 If switching to transdermal fentanyl: 
  Use calculated equianalgesic dose included in product information  (approx. OME/2) 
 
On the basis of assessment of severity of pain severity and other medical/psychologic characteristics, increase or 
decrease the calculated dose by 15-30% to increase the likelihood that the initial dose will be effective, or 
conversely, unlikely to cause withdrawal or side-effects 
 
If a supplemental (breakthrough) dose is used, calculate this dose at 10-20% of the total daily dose (OME) and 
administer at an appropriate interval 
 
Exception:  transmucosal fentanyl formulations should always be initiated at lower doses and titrated 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCN Opioid Analgesics and Organ System Dysfunction     124 
 
System Failure   Preferred  Consider  Avoid 
 
Hepatic    hydromorphone oxycodone  fentanyl 
    methadone     hydrocodone 
    morphine     tramadol 
     
Renal    methadone  hydromorphone morphine 
    fentanyl  hydrocodone  codeine 
    oxycodone     tramadol 
     
Hepatic + Renal   methadone  fentanyl  morphine 
    hydromorphone oxycodone  codeine 
          tramadol 
          hydrocodone 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCN Opioid Dose Size Availability       125 
Morphine IR  15, 30 
   Oral solution 1mg/ml, 2mg/ml, 4mg/ml, 20mg/ml 
Morphine SR  15, 30, 60, 100 
 
Oxycodone IR  5, 15, 30 
   Oral solution 1mg/ml, 20mg/ml 
Oxycodone SR  10, 15, 20, 30, 40, 60, 80 
 
Hydromorphone 2,4,8 po tablets 
 
Fentanyl  lozenge – 2000, 400,600, 800, 1200, 1600 mcg 
   buccal – 100, 200, 400, 600 800 mcg 
   transdermal – 12, 25, 50, 75 mcg/hr 
 
Methadone  5, 10  
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Opioid Risk Variables 
Family History 
 Alcohol, Illegal Drugs, Prescription agents 
Personal History 
 Alcohol, Illegal Drugs, Prescription agents 
Age (16-45) 
History preadolescent sexual abuse 
Psychologic/Psychiatric Disease: ADD, OCD, Bipolar, Schizophrenia, Depression 
 
 
Aberrant Behaviors – more predictive: 
 Selling prescription drugs 
 Prescription forgery 
 Stealing/”borrowing” 
 Injecting oral drugs 
Multiple drugs 
Unsanctioned escalation 
Resisting change despite side effects 
Prescription losses 
 
Aberrant Behaviors – less predictive: 
 Aggressive complaining about need for increased doses 
 Drug hoarding 
 Specific drug request 
 Use of drug to treat other symptoms 
 Multiple escalations 
  
 
 
 
 
 
 
 
 
 
 
 
 
PCN Urine Drug Testing         127 
Drug:   Metabolite(s):     Duration (days): 
Codeine   codeine, morphine, hydrocodone   2-4 
Morphine  morphine, hydromorphone,  codeine  2-4 
Hydrocodone  hydrocodone, hydromorphone   2-4 
Hydromorphone  hydromorphone     2-4 
Oxycodone  oxycodone, oxymorphone, hydrocodone  2-4 
Oxymorphone  oxymorphone, oxycodone    2-4 
 
Alprazolam  alprazolam, alpha-hydroxyalprazolam  up to 7 
Clonazepam  7-aminoclonazepam    up to 7 
Chlordiazepoxide  nordiazepam, oxazepam    up to 7 
Diazepam  nordiazepam, temazepam, oxazepam  up to 7 
Flurazepam  2-hydroxyethyl flurazepam   up to 7 
Lorazepam  lorazepam     up to 7 
Oxazepam  oxazepam     up to 7 
Temazepam  oxazepam     up to 7 
 
Barbituates        up to 6  
Cocaine         2-4 
Alcohol         0.25-0.5 
THC         up to 5 
PCP         2-7 
 
Opioids         2-4   
Methadone        2-4 
Propoxyphene        2-4 
Tramadol        2-4  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCN Methadone Notes        128 
Convert PO Methadone to IV Methadone: Total Methadone Dose/2 
 Infused over 24 hrs or divided q6-8 hr 
 
Convert 24 hour Oral Morphine Equivalent (OME) to equianalgesic Morphine dose: 
 OME  Ratio OME to 24 hr PO Methadone dose 
 <60  “opioid naïve” – Methadone 2.5 mg bid or tid 
 60-200  10:1 (less than 65 years old) 
 >200  20:1 (or if greater than 65 years old) 
 
 (consider Fixed dose Methadone of 30 mg when OME > 300) 
 
Adjust (decrease) calculated dose of Methadone up to 50%: 
 Incomplete cross tolerance 
 Varied metabolism 
 Imperfection of equianalgesic tables 
 
Dose should not be increased before 5-7 days and not increased by more than 5-10 mg/day once a total 
daily dose of 30-40 mg has been reached 
 
ECG evaluation for QTc prolongation based on clinical judgment 
 
Methadone Interactions 
 CYP450 inhibition > increase effect 
  Macrolides – clarithromycin, erythromycin 
  diltiazem, verapamil 
   ketoconazole 
  itraconazole 
  cyclosporine 
  grapefruit juice 
 CYP450 induction > decrease effect 
  phenobarbital 
  phenytoin 
  carbamazepine 
  ritonavir 
 
 
Estimate of Methadone to Morphine Conversion   (JPM 2008;11:1103) 
 1 mg Methadone PO = 4.7 mg Morphine PO 
 1 mg Methadone IV = 13.5 mg Morphine PO 
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PCN Methadone Notes 2 
 
This table incorporates: 
 Incomplete cross tolerance 
 Variations in metabolism 
 Imperfections in equianalgesic tables 
 
Ø Do not decrease after conversion 
 
 
OME mg/24 hrs   Morphine to Methadone Ratio 
 
Less than 100     3:1 
101-300     5:1 
301-600     10:1 
601-800     12:1 
801-1000     15:1 
Greater than 1000    20:1 
 
 
Oral methadone to IV methadone = 2:1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCN Fentanyl (F) Notes         130 
For bolus dosing:  100 mcg (0.1 mg) F = 10 mg Morphine IV = 30 mg Morphine PO 
For continuous infusion: 100 mcg (0.1 mg) F/hr = 6.6 mg Morphine/hr 
 
F TTD to F IV: decrease by 50% 
F IV to F TTD: 1:1 
OME to F TTD: OME/2 
 
F IV peak effect 6-10 min, duration 30-90 min 
 
F TTD doses available: mcg/hr 12, 25, 50, 75, 100 
 
F oral lozenge (Actiq) = OTFC 
 200 mcg OTFC  = 12 mg Morphine PO 
    2-4 mg Morphine IV 
    7.5 mg oxycodone PO 
 
OTFC mcg doses sizes available: 200, 400, 600, 800, 1200, 1600 
 
F buccal tablets (Fentora):  2X strength of OTFC 
 dose sizes available: 100, 200, 400, 600, 800 
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PCN Fentanyl Notes 2 
50 mcg/hr Fentanyl TD = OME 100 
IV Fentanyl 
 Peak effect IV push = 6-10 minutes 
 Duration of effect = 30-90 minutes 
 
Conversion to IV Fentanyl: 
 100 mcg IV Fentanyl = 10 mg IV Morphine 
  (for bolus dosing or do not decrease for cross tolerance) 
 100 mcg Fentanyl IV = 6.6 mg Morphine Sulfate 
  (for continuous infusion) 
 
TransDermal to IV Fentanyl  -  decrease by 50% 
IV to TD   -  1:1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCN Aberrant Behavior Risk       132 
      Female Score  Male Score 
Family History EtOH     1   3 
Family History Illegal Drugs    2   3 
Family History Prescription Drugs   4   4 
Personal History EtOH    3   3 
Personal History Illegal Drugs    4   4 
Personal History Prescription Drugs   5   5 
Age 16-45      1   1 
History Preadolescent Sexual Abuse   3   0 
Psychological Disease 
 ADD      2   2 
 OCD      2   2 
 Bipolar      2   2 
 Depression     1   1 
      __________     ____________ 
 
 
Low Risk 0-3 Moderate Risk 4-7 High Risk 8 or more 
 
Psychological Variables Potentially Implicated in Opioid-Related Mortality 
 Fear and desperation in the face of pain (catastrophizing) 
 Impulsivity 
 Chemical coping 
 Lack of acceptance 
 Personal disorder (“borderline”) 
  A: odd, eccentric 
  B: emotional overreactivity, self destructiveness, repetitive acting out 
  C: anxious, avoidant 
 Demoralization, existential distress 
 Sensation seeking 
 Escapism  
 
 
 
 
 
 
 
 
Categories of Interventions for Cancer Pain      133 
 
Pharmacological 
   Opioid analgesics 
   Non-opioid analgesics 
   Adjuvant analgesics 
    
Interventional 
   Injection therapies 
   Neural blockade 
   Implant therapy 
 
Rehabilitative 
   Modalities 
   Therapeutic exercise 
   Occupational therapy 
   Hydrotherapy 
    
Psychological 
   Psychoeducational interventions 
   Cognitive-behavioral therapy 
   Relaxation therapy 
   Guided imagery 
   Other stress management and psychotherapy 
 
Neurostimulation 
   Transcutaneous 
   Transcranial 
   Implanted 
 
Integrative (complementary, alternative) 
   Acupuncture 
   Massage 
   Physical movement 
   Others  
 
 
 
 
 
 
 
 
Psychoactive Meds        134 
SSRI:     mg dosage 
 Citalopram (Celexa) 20-80 
 Fluoxetine (Prozac) 20-80 
 Paroxetine (Paxil)  20-80 
 Sertraline (Zoloft)  50-300 
 
 Fewest drug/drug interactions: citalopram, sertraline 
 Sedation, discontinuation syndromes: paroxetine 
 
SNRI: 
 Venlafaxine (Effexor) 37.5-300 
 Duloxetine (Cymbalta) 20-120 
   for neuropathic pain at least 60 mg qd 
 
Atypical: 
 Bupropion (Wellbutrin) 100-450 seizure risk 
 Mirtazapine (Remeron) 15-45  increased appetite, weight gain 
 
2nd generation Anti-Psychotic Agents: 
 Haloperidol (Haldol) 2.5-15 
 Risperidone (Risperdal) 1-6 
 Olanzapine (Zyprexa) 2.5-30 
 Aripiprazole (Abilify)  5-30 
 Quetiapine (Seroquel) 25-800 
 Clozapine  (Clozaril) 250-450 
 
Benzodiazepines:     equivalent PO dose mg 
 Alprazolam (Xanax)  0.25-3  0.5 
 Clonazepam (Klonopin) 0.25-3  0.25 
 Diazepam (Valium) 2.5-20  5.0 
 Lorazepam (Ativan) 0.5-5  1.0 
 
 Flurazepam (Dalmane) 15-30  30 
 Temazepam (Restoril) 10-20  20 
 
GABAa – Sleep Agents: 
 Zaleplon (Sonata) 5-10 
 Zolpidem (Ambien) 5-10 
 
Other: 
 Buspirone (Buspar) 10-45 
 Trazodone   25-100 
PCN Anti-Depressant Agents – Notes       135 
Escitalopram  5-20 qd   fewer interactions 
Citalopram  10-40 qd  fewer interactions 
Fluoxetine  5/10-60 qd  longer half-life, taper when discontinuing 
Paroxetine  10 qPM – 40  sedating, significant interactions 
Sertraline  12.5/25-200 
Venlafaxine  37.5 qAM or bid-150 bid stimulating (not use with anxiety), taper 
Duloxetine  10/20 q AM -60 bid  use with coexistent anxiety 
       Nausea, dry mouth, constipation 
Desipramine  10/25 qhs- 150/day  
Nortriptyline  10 qhs – 150  fewer anti-cholinergic side effects 
Mirtazapine  7.5/15 qhs-60  sedation, weight gain 
      NE, 5HT antagonist 
Bupropion  75-100 qAM – 450/day useful with fatigue, low energy 
      not with seizures, bulimia, anorexia 
      weak NE, 5HT, Dop antagonist 
Methylphenidate 2.5/5 qAM or noon side effects:  nervousness, agitation 
- 60/day 
 
 
Citalopram reduces agitation, anxiety 
  Not as activating as fluoxetine 
  Not as sedating as paroxetine 
  “neutral 
Mirtazapine sedation, increased appetite, enhances effect of Coumadin 
  not effective for pain 
  consider with combination of nausea/anorexia/insomnia/depression 
Fluoxetine activating 
Bupropion activating 
Duloxetine better tolerated in elderly 
  consider with depression/anxiety/neuropathic pain in elderly 
 
Tri-cyclic agents: contraindicated with CHF, liver failure, BPH 
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PCN – Antidepressant Medication Considerations (CoMorbid Neuro/Med and Psych Symptoms) 
Symptom(s)    Consider   Avoid 
 
Depression+ 
 Anxiety    SNRI 
 OCD    Fluoxetine   TCA, Bupropion 
 Psychosis    SSRI, SNRI + Anti-psych  TCA, Bupropion 
 Somatization   Duloxetine   TCA 
 Abulia    Bupropion   TCA, Paroxetine 
 Delerium or Dementia  Citalopram   TCA, Bupropion 
 Fatigue    Bupropion, Fluoxetine  TCA, Paroxetine 
 Insomnia    Mirtazapine   TCA, Fluoxetine 
 Pain    Duloxetine, TCA   SSRI 
 Parkinsonism   Bupropion, Mirtazapine  Sertraline, Paroxetine 
 Seizures    SSRI, SNRI   Bupropion 
 Tremor    Mirtazapine   SSRI, SNRI 
 Stroke    Citalopram   TCA 
 Vertigo    Fluoxetine   TCA 
 Advanced Age   Citalopram, Bupropion  TCA 
 Constipation   Bupropion, SSRI, SNRI  TCA 
 Diarrhea    Mirtazapine, TCA   SSRI, Bupropion 
 DM    Bupropion, SSRI, SNRI  TCA, Paroxetine 
 Glaucoma   Bupropion, SSRI, SNRI  TCA 
 Heart Disease   SSRI    TCA, Mirtazapine 
 Hypotension   Bupropion, SNRI   TCA 
 Renal Failure   Fluoxetine   Bupropion 
 Hepatic Failure   Bupropion   Duloxetine, Citalopram 
 Nausea, GERD       Paroxetine, Sertraline 
 Overweight   Bupropion   TCA, Mirtazapine 
 Pregnancy   SSRI, SNRI   TCA 
 Sexual Dysfunction   Bupropion   Paroxetine, SSRI 
 Smoker    Bupropion   TCA 
 Urine Retention   Bupropion   TCA   
 
 
 (SSRI,SNRI,Bupropion,Mirtazapine) 
 -no agent superior for associated pain, anxiety, insomnia 
 -higher incidence of side effects: 
  Venlafaxine > nausea 
  Sertraline > diarrhea 
  Mirtazapine > weight gain 
  Bupropion > less sexual dysfunction 
  Mirtazapine > faster onset of action 
 
Anti-Anxiety Agents – Notes        137 
 
Alprazolam   0.25-2 tid/qid   peak 30  minutes, ++ rebound 
Lorazepam  0.5-1.5 bid/qid  peak 5-20 min, ½ life 13-15 hrs 
Clonazepam  0.25-2 bid/tid   peak 20-60 min, ½ life 19-50 hrs 
Diazepam  2-10 bid/qid   peak 15-45 min, ½ life 20-50 hrs 
       metabolites 50-100 hrs 
 
Buspirone  5-10 bid/tid   peak 1-1.5 hrs, ½ life 2-11 hrs 
 
Haloperidol  0.5-5 q2-12 hrs 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 NSAID Notes          138 
NSAID Classes: 
 Propionic acids 
  Fenoprofen 
  Ibuprofen 
  Ketoprofen 
  Naproxen 
 Acetic acids 
  Diclofenac 
  Indomethacin 
Ketorolac 
Sulindac 
Tolmentin 
 Endic acids 
  Meloxicam 
  Piroxicam 
 Anthranilic acids 
  Mefenamic acid 
 
 
Risk for GI complications: 
 Prior ulcer, GI bleed 
 Age > 60 
 High dose 
 Concurrent steroids 
 Concurrent anticoagulation 
 
 1 or 2 variables:  moderate risk, use cytoprotective agent concurrently 
 More than 2 variables: “don’t use” 
 
 
 Other contraindications: 
  Strong history CV disease 
  Hypercoagulable state 
  Renal disease/failure 
  Low perfusion state 
 
 
PCN Ketamine Notes        139 
Sub-anesthetic (off-label) uses for pain management 
 MNDA channel blockade – involved in central (dorsal horn) sensitization 
 Consider for: neuropathic pain 
 opioid-induced hyperalgesia (opioid alternative) 
Continuous IV infusion: 0.05-0.3 mg/kg/hr 
PO Ketamine: liquid – dilute to 50 mg/ml 
  start 10-25 mg tid to qid, titrate in steps of 10-25 mg 
   usual effective dose 100-300 mg/day 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCN Malignant Epidural Spinal Cord Compression (MESCC)    140 
 
Surgery Indications:  
 Spinal instability 
 Previous RT 
 Worse despite RT 
 Radioresistant tumor 
 Unknown primary 
 Paraplegia less than 48 hrs 
 Single area of compression 
 
Steroid dosing: dexamethasone 
 
 “high dose” – if neuro exam abnormal 
 96 mg bolus IV, 24 q 6 hr po x 3 days 
 10 day taper 
 
 “moderate dose” – all others 
 10 mg bolus IV, 4 qid 
 2 week taper 
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PCN:  Nausea/Vomiting 
 Nervous System Pathways/Mechanisms/Receptors 
 Correlation of Mechanisms/Receptors with Medications 
 
4 pathways:      
Chemoreceptor Trigger Zone (CTZ)   
Cortex       
Peripheral 
 Gastrointestinal (GI)    
 Serosa      
 Viscera      
Vestibular      
Receptors: 
Acetylcholine (Ach)/Muscarinic(m) 
Dopamine-2 (D2) 
Histamine (H1) 
Neurokinin (NK) 
5-hydroxytryptamine-2 (5-HT2) 
5-hydroxytryptamine-3 (5-HT3) 
 
CTZ, opiods > D2 >  metoclopramide, prochlorperazine, chlorpromethazine, haloperidol, 
   olanzapine 
 
ChemoRx, RT, opioids, uremia, post-op > 5-HT3> 
   ondansetron, dexamethasone 
 
Bowel obstruction > D2, Ach > 
   metoclopramide, haloperidol/olanzapine, dexamethasone, hyoscyamine 
 
Motion > H1 >  scopolamine, diphenhydramine, promethazine 
 
Sample Agents: 
Metoclopramide   D2 (GI), 5HT2 
Prochlorperazine  D2 (CTZ) 
Chlorpromazine  D2 (CTZ) 
Promethazine  D2, H1, Ach 
Diphenhydramine H1 
Scopolamine  Ach 
Hyoscyamine  Ach 
 
Ondansetron  5HT3 
Mirtazapine  5HT3 
 
Olanzapine  D2, Ach, H1, 5HT3 
Haloperidol  D2 
Propofol   5HT3 
142 
PCN NYHA Heart Failure Classification 
Symptoms = fatigue, dyspnea, palpitations, angina 
I: cardiac disease without resulting limitation of physical activity 
 ordinary physical activity does not cause symptoms 
 
II: cardiac disease resulting in slight limitation of physical activity 
 comfortable at rest 
 ordinary physical activity results in symptoms 
 
III: cardiac disease with limitation of physical activity 
 comfortable at rest 
 less than ordinary physical activity causes symptoms 
 
IV: cardiac disease resulting in inability to carry out any physical activity 
 symptoms present even at rest 
 if any physical activity is undertaken, discomfort is increased 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCN LVAD Issues to consider       143 
 
Device Failure/infection 
Artificial nutrition/hydration 
Transfusions 
Renal replacement therapy 
Mechanical ventilation 
Organ donation 
 
Comorbidities 
 Stroke 
 Sepsis 
Renal failure 
 
Catastrophic event 
 
Peri-operative mortality/morbidity 
Rehabilitation plans 
 
Quality of life 
Goals/expectations 
Psychosocial assessment 
Spiritual/religious preferences 
 
Reference: Swetz, LVAD Preparedness Plan 
  Mayo Clinic Proceedings 
  2011;86(6):493 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCN SCCM Guidelines Pain/Agitation/Delerium       144 
  Agitation in critically ill patients may result from inadequately treated pain, anxiety, 
delirium, and/or ventilator dysynchrony. 
  Detection and treatment of pain, agitation, and delirium should be reassessed often in 
these patients. 
  Patients should be awake and able to purposely follow commands in order to 
participate in their care unless a clinical indication for deeper sedation exists. 
Assess and Treat Statements and Recommendations 
  Pain assessment should be routinely performed in all ICU patients (1B). 
  Self report is preferred over the use of behavioral pain scales to assess pain in ICU patients who are 
able to 
communicate (B). 
  The BPS and CPOT are the most valid and reliable behavioral pain scales for use in ICU patients who 
cannot communicate (B). 
  Vital signs should not be used alone to assess pain, but they may be used adjunctively for pain 
assessments (2C). 
  Preemptively treat chest tube removal with either analgesics and/or non-pharmacologic therapy (1C). 
  Suggest preemptively treating other types of procedural pain with analgesic and/or non-pharmacologic 
therapy (2C). 
  Use opioids as first line therapy for treatment of non-neuropathic pain (1C). 
  Suggest using non-opioid analgesics in conjunction with opioids to reduce opioid requirements and 
opioid-related side effects (2C). 
  Use gabapentin or carbamazepine, in addition to intravenous opioids, for treatment of neuropathic pain 
(1A). 
  Use thoracic epidural for postoperative analgesia in abdominal aortic surgery patients (1B). 
  Suggest thoracic epidural analgesia be used for patients with traumatic rib fractures (2B). 
  Depth and quality of sedation should be routinely assessed in all ICU patients (1B). 
  The RASS and SAS are the most valid and reliable scales for assessing quality and depth of sedation 
in ICU patients (B). 
  Suggest using objective measures of brain function to adjunctively monitor sedation in patients 
receiving neuromuscular blocking agents (2B). 
  Use EEG monitoring either to monitor non-convulsive seizure activity in ICU patients at risk for seizures, 
or to titrate electrosuppressive medication to achieve burst suppression in ICU patients with elevated 
intracranial pressure (1A). 
  Target the lightest possible level of sedation and/or use daily sedative interruption (1B). 
  Use sedation protocols and checklists to facilitate ICU sedation management (1B). 
  Suggest using analgesia-first sedation for intubated and mechanically ventilated ICU patients (2B). 
  Suggest using non-benzodiazepines for sedation (either propofol or dexmedetomidine) rather than 
benzodiazepines (either midazolam or lorazepam) in mechanically ventilated adult ICU patients (2B). 
  Delirium assessment should be routinely performed in all ICU patients (1B). 
  The CAM-ICU and ICDSC delirium monitoring tools are the most valid and reliable scales to assess 
delirium in ICU patients (A). 
  Mobilize ICU patients early when feasible to reduce the incidence and duration of delirium, and to 
improve functional outcomes (1B). 
  Promote sleep in ICU patients by controlling light and noise, clustering patient care activities, and 
decreasing stimuli at night (1C). 
  Avoid using rivastigmine to reduce the duration of delirium in ICU patients (1B). 
  Suggest avoiding the use of antipsychotics in patients who are at risk for torsades de pointes (2B). 
  Suggest not using benzodiazepines in ICU patients with delirium unrelated to ETOH/benzodiazepine 
withdrawal (2B). 
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PAIN 1. ICU patients routinely experience pain at rest and with ICU care (B). Pain in cardiac surgery145 
patients, especially women, is poorly treated (B). Procedural pain is common in ICU patients (B). 
2. Perform routine pain assessment in all patients (1B). In motor intact patients unable to self report, we 
suggest using behavioral pain scales rather than vital signs to assess pain (2C). The BPS and CPOT are 
the most valid and reliable behavioral pain scales (B). Vital signs should only be used as a cue for further 
pain assessment (2C). 
3. For non-neuropathic pain, use intravenous opioids as first line analgesic therapy (1C); use non-opioid 
analgesics to reduce opioid side effects (1C); and use either gabapentin or carbamazepine in conjunction 
with intravenous opioids for neuropathic pain (1A). 
4. Suggest preemptively treating procedural pain (2C), especially chest tube removal (1C). 
5. Use thoracic epidural analgesia for abdominal aortic surgery (1B), and suggest also using for traumatic 
rib fractures (2B). No evidence guides the use of lumbar epidural analgesia for abdominal aneurysm 
surgery (0A), or thoracic epidural analgesia for either intrathoracic or nonvascular abdominal surgical 
procedures (0B). No evidence guides the use of regional vs. systemic analgesia in medical ICU patients  
 
AGITATION 1. Maintaining lighter levels of sedation in ICU patients is associated with improved clinical 
outcomes (B); light levels of sedation should be maintained in these patients (1B). 
2. The RASS and SAS scales are most valid and reliable instruments for assessing adequacy and depth 
of sedation (B). 
3. Use Brain Function monitors only as adjuncts to subjective sedation scales in unparalyzed patients 
(1B), but suggest using brain function monitors to primarily monitor depth of sedation in patients receiving 
neuromuscular blocking agents (2B). 
4. Use EEG monitoring to monitor non-convulsive seizure activity in ICU patients at risk for seizures, and 
to titrate burst suppression therapy in ICU patients with elevated intracranial pressure (1A). 
5. Use either use daily sedative interruption or titrate sedative medications to maintain light levels of 
sedation (1B). Suggest using Analgesia-first sedation (2B). Suggest using non-benzodiazepines rather 
than benzodiazepine infusions for sedation (2B). Use sedation protocols and daily checklists to integrate 
and to facilitate management of pain, sedation, and delirium in ICU patients (1B). 
 
1. Delirium is associated with increased mortality (A), prolonged ICU and hospital LOS (A), and post-ICU 
cognitive impairment (B). 
2. Delirium risk factors include: pre-existing dementia, HTN, history of alcoholism, and a high severity of 
illness at baseline (B); coma (B); and benzodiazepine use (B). Mechanically ventilated ICU patients at risk 
for delirium have a lower delirium prevalence when treated with dexmedetomidine rather than with 
benzodiazepines (B). 
3. Routinely monitor ICU patients for delirium (1B). The CAM-ICU and ICDSC are the most valid and 
reliable instruments for this purpose (A). 
4. Pursue early mobilization to reduce the incidence and duration of delirium (1B). 
5. Suggest not using either haloperidol or atypical antipsychotics prophylactically to prevent delirium (2C). 
6. Promote sleep in adult ICU patients by optimizing patients’ environments, using strategies to control 
light  and noise, to cluster patient care activities, and to decrease stimuli at night in order to protect 
patients’ sleep cycles (1C). 
7. Do not use rivastigmine to reduce the duration of delirium in ICU patients (1C). 
8. Suggest withholding antipsychotics in patients with baseline QT prolongation, a history of Torsades de 
Pointes, or in those receiving concomitant medications known to prolong the QT interval (2C). 
9. When sedation is required in delirious ICU patients, suggest using dexmedetomidine rather than 
benzodiazepine infusions for sedation in these patients, unless delirium is related to either alcohol or 
benzodiazepine withdrawal  
Pocket card summarizing specific pain, agitation, and delirium (PAD) guideline statements and recommendations (back side). BPS = Behavioral Pain Scale; CPOT 
= Critical-Care Pain Observation 
Tool; RASS = Richmond Agitation and Sedation Scale; SAS = Sedation-Agitation Scale; EEG = electroencephalography; CAM-ICU = Confusion Assessment Method 
for the ICU; ICDSC = ICU Delirium 
Screening Checklist; ETOH = ethanol; LOS = length of stay; HTN = hypertension. 
Barr J, Gilles, LF, Puntillo K, et al. Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit. Crit 
Care Med. 2013;41:263-306 
Withdrawal of Life-Sustaining Measures   146 
Most patients who die in ICU and acute-care settings do so after a decision to limit life-
sustaining treatments. Physicians have an important responsibility to improve the process by 
which life-sustaining treatments are withheld or withdrawn. Although little empiric evidence is 
available to guide clinicians in the practical aspects of withdrawing life-sustaining treatments, 
ICU physicians should thoroughly understand the goals of withdrawing life-sustaining treatments 
(to remove all treatments no longer desired or indicated while ensuring patient comfort during 
the process) and should develop expertise in withdrawing life-sustaining treatments in order to 
minimize patient symptoms and support the family.  
Withdrawal of life-sustaining treatments is a clinical procedure; physicians must have the same 
preparation and expectation of its quality as for other procedures. The rationale for the decision 
to withdraw life support should be documented in the medical record. Several topics should be 
discussed with families, including explaining how interventions will be withdrawn, how the 
patient’s comfort will be ensured, the patient’s expected length of survival, and family or patient 
preferences about other aspects of end-of-life care. An explicit plan for performing the procedure 
and handling complications should be formulated. The patient should be in the appropriate 
setting with irrelevant monitoring removed; the process should be carefully documented, 
including reasons for increasing sedation or analgesia; and outcomes should be evaluated to 
improve the quality of future care.  
Once a decision is made and a time is set to withdraw life-sustaining treatments, the course and 
timing of withdrawal should be determined by the potential for patient discomfort as treatment is 
stopped. Although time should be provided for family to say goodbye, the only rationale for 
tapering life-sustaining treatment is to allow time to meet the patient’s needs for symptom 
control. Vasopressors, antibiotics, nutrition, or most other critical care treatments can be 
discontinued immediately, without tapering. Mechanical ventilation is one of the few life-support 
treatments for which abrupt termination can lead to discomfort; consequently, physicians have a 
responsibility to develop an approach to terminal ventilator discontinuation that ensures patient 
comfort. A protocol that explicitly details an approach to withdrawal of life support in the ICU, 
including mechanical ventilation, has been associated with high ratings of clinician satisfaction 
and may help improve the quality of care, especially in settings where physicians are not familiar 
with withdrawal of life support or where there is significant practice variation. A sample protocol 
devised for withdrawal of mechanical ventilation is shown in Table 1. Physicians also should 
inform families that, while death is expected after withdrawal of support, it may not be certain 
and the timing can vary.  
Any protocol for withholding life-sustaining treatments should include an explicit protocol for 
sedation and analgesia during this procedure. Such a protocol, carefully developed and 
implemented, has been associated with high levels of physician and nurse satisfaction, as well as 
with increased use of opiates and benzodiazepines for some patients without change in time from 
ventilator withdrawal to death. Furthermore, higher  
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doses of opiates and benzodiazepines in the context of withdrawing mechanical ventilation has 
been shown to be associated with no change or an actual increase in time from withdrawal of 
mechanical ventilation to death, suggesting that these drugs can be used to provide for patient 
comfort without hastening death.  
 
Table 1  
Sample Protocol for Terminal Withdrawal of Mechanical Ventilation Previously Developed and 
Evaluated* 
1. Initial ventilator setting: IMV rate __, PS level __, (choose IMV or PS, not both), Fio2 __, 
PEEP __  
2. Reduce apnea, heater, and other ventilator alarms to minimum setting 
3. Reduce Fio2 to room air and PEEP to zero over < 5 min and titrate sedation as indicated for 
discomfort  
4. As indicated by level of comfort, wean IMV to 4 or PS to 5 over 5 to 20 min; titrate sedation 
for comfort 
5. When patient is comfortable on IMV rate 4 or PS of 5, select one of the following: 
Extubate patient to air  
T-piece with air (not CPAP on ventilator)  
• IMV = intermittent mandatory ventilation; PS = pressure support; Fio2 = fraction of 
inspired oxygen; PEEP = positive end-expiratory pressure; CPAP =continuous positive 
airway pressure.  
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PCN Communication 1 
5 Key Elements of Patient-Centered Communication (Gustin) 
 
 Assess Patient Perspective ------------------------------------------------- Manage Uncertainty 
  I        I 
  I   Shared Decision-Making  I 
  I        I 
 Exchange Information ------------------------------------------------------ Attend To Emotion 
 
 
 
 
 
Mnemonics: 
 
SPIKES 
 S: Setting up interview 
 P: assessing patient Perception/Perspective 
 I: obtaining patient Invitation 
 K: giving Knowledge and information 
 E: addressing patient Emotions 
 S: Strategies and Summary 
 
VALUE 
 V: Value patient/family input 
 A: Acknowledge emotion 
 L: Listen 
 U: Understand patient as a person 
 E: Elicit concerns 
 
NURSE 
 N: Name 
 U: Understand 
 R: Respect 
 S: Support 
 E: Explore 
 
ASCEND 
 A: Anticipate – preplanning 
 S: Summarize patient/family understanding 
 C: Acknowledge Concerns 
 E: Explore and Explain 
 N: Next steps 
 D: Document 
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PCN Spiritual Assessment/Management 
Spirituality (meaning, hope, relationships, forgiveness) 
Existential (how and whether life has meaning and why we exist) 
Palliative Care Practitioner Role in Spiritual Healing 
 Be:  Human 
   Real 
   Honest  
 Be:  Present 
   Listen 
 Be:  Sensitive to spiritual needs 
 Respect: Belief systems 
 Include: In intervention plan 
 
 Simple Questions: 
  Do you have any spiritual or religious concerns at this point? 
  Are there spiritual resources that could help you at this point 
 
On-line resource: George Washington Institute for Spirituality and Health (GWish) 
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Criterion:    Understanding 
 Patient Ability:  grasp fundamental meaning of information communicated 
 Assessment Approach: encourage paraphrasing of disclosed information regarding condition and treatment 
 Sample Questions:  “please tell me in your own words…”: 
      “the problem with your health now” 
      “the recommended treatment” 
      “the possible risks and benefits of the treatment” 
      “any alternative treatments and their risks/benefits” 
      “risks and benefits of no treatment” 
 Comment:   information to be understood includes nature of condition, nature and purpose of  
     proposed treatment, possible risks and benefits of that treatment, and alternative  
     approaches – including no treatment 
 
Criterion:    Appreciation 
 Patient Ability:  acknowledge medical condition and likely consequences of treatment options 
 Assessment Approach: ask for description of perspective on medical condition, proposed treatment, 
     likely outcomes 
 Sample Questions:  “what do you believe is wrong with your health now?” 
     “do you believe that you need some kind of treatment?” 
     “what is treatment likely to do for you?” 
     “what makes you believe it will have that effect?” 
     “what do you believe will happen if you are not treated?” 
     “why do you think (this treatment) has been recommended?” 
 Comment:   consider that patients who do not recognize their illnesses (“lack of insight”) 
     cannot make valid decisions about treatment; delusions or pathologic levels of  
     distortion or denial are the most common causes of impairment in this criterion 
 
Criterion:    Deliberation/Reasoning 
 Patient Ability:  demonstrate rational process of manipulating the relevant information 
 Assessment Approach: ask for comparison of treatment options/consequences and reasons for choice 
 Sample Questions:  “how did you decide to accept or reject the recommended treatment?” 
     “what makes (chosen option) better than (alternative option) for you?” 
 Comment:   focus on process of decision-making, not outcome; patients have right to make 
     “unreasonable” choices 
 
Criterion:    Communication 
 Patient Ability:  clearly indicate a treatment choice    
 Assessment Approach: ask patient to identify/indicate a treatment choice 
 Sample Questions:  “have you decided to follow a recommendation for treatment?” 
     “can you tell me what that decision is?” 
      OR “what is making it hard for you to decide” 
 Comment:   frequent reversals of choice because of psych/neuro conditions may indicate 
     lack of capacity” 
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Pathways to EOL 
 Non-Escalation of Life Prolonging Therapies 
  Mode of Death: Progression of Underlying Disease 
   Comments: 
Difficult to control or predict exactly when and how death will occur 
Allow family to recognize dying as a consequence of disease progression and beyond their 
control 
Blood transfusions and antibiotics may provide comfort and should be judged on the basis of 
their  
  actual effects on comfort (e.g. fluid overload versus improved energy level) 
 
 Compassionate Extubation 
  Mode of Death: Hypoxia, hypercarbia, acidosis, hemodynamic collapse 
   Comments: 
Allows for a rapid death if lung disease is severe or if patient has no respiratory drive 
Prepare for possible secretions, anxiety, dyspnea 
Stop neuromuscular blockade prior to extubation 
Consider pre-medication to help alleviate symptoms 
 
 Cessation of Hemodynamic Support (Inotropes, Vasopressors, ECMO) 
  Mode of Death: Hypotension progressing to acidosis, shock, coma 
   Comments: 
Hypotension can result in significant sedation 
Death may be rapid if patient is on significant hemodynamic support or may be hours to days if 
on 
  lesser degrees of hemodynamic support 
Can precipitate symptoms of heart failure or ischemia 
 
 Discontinuation of Dialysis 
  Mode of Death: Acidosis, Electrolyte Disturbances, Uremia, Fluid Overload, 
   Comments 
Uremia can cause sedation 
Symptoms of fluid overload be distressing-prepare family and treat symptoms appropriately 
Typically a prolonged course (days to weeks) 
However, death can ultimately be rapid (hyperkalemia with cardiac arrest) 
 
 Withholding of Artificial Nutrition or Fluid 
  Mode of Death: Dehydration and Underlying Condition (NOT Starvation) 
   Comments: 
Aids with comfort related to fluid status and digestive system shutting down 
Hunger and thirst lessen after 1-2 days with an increase in ketones and release of endogenous  
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endorphins which can have an analgesic effect 
Death tends to occur within days to weeks (reported range 2-37 days) and often during sleep 
Requires good mouth care 
 
Dramatic physical changes can occur: significant weight loss, skin changes, sunken eyes,  
  concave abdomen, abnormal respiration (including prolonged apnea) 
Emotionally charged topic: important to have a consensus among team to provide a united  
  front 
Provide emotional support to family around concern for “starving” or “killing” their child, legal 
  ramifications of decisions, judgment of extended family and friends 
Avoid use of terms “withdrawal of care” and “reduction of care”; instead use terms such as  
  “focus on comfort and quality of life” or “preventing suffering” 
Care itself is never withdrawn, goals for care have changed while care often intensifies in other  
  ways 
Difficult care choices are ideally made when there is consensus among patients, parents,  
  providers 
However, in some cases it can be important to emphasize that decisions are provider-directed  
  to minimize parental feelings of burden and guilt 
Limit invasive tests or monitoring that do not promote comfort 
Some parents want to know how long their child will live 
Guide parents by speaking in terms of minutes/hours, hours/days, days/weeks,  
 weeks/months 
Acknowledge that it is difficult to predict length of survival-Examples: 
 
 “It is hard for us to know and we find that when we make predictions we are frequently  
Wrong. Based on _____’s medical situation, my best estimate would be ______.  It is 
important to know, however that children often surprise us and may live longer or 
shorter than we anticipate, so it is important that we are prepared for both situations” 
 
“Based on how much support ______is currently receiving, we expect he/she will die 
within _________ Some kids do surprise us, though, and it is possible that he/she could 
live for a longer time.  Regardless of what happens, we are ready to keep ________ 
comfortable.” 
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 Dyspnea 
  Pharmacologic 
   Opioids are the primary treatment for dyspnea at EOL 
   Opioid dose generally 25% of the amount used for pain 
   Consider lorazepam as an adjunct 
  Non-Pharmacologic 
   Oxygen 
   Elevate head of bed 
   Bedside fan 
   Fluid restriction 
 
 Secretions 
  Pharmacologic 
   Glycopyrrolate 
  Non-Pharmacologic 
   Fluid restriction 
   Gentle suction 
   Reposition         
Educate families that noisy breathing may occur when death is imminent 
May be distressing to hear but the child likely does not experience 
 discomfort 
  
 Agitation/Anxiety 
  Pharmacologic 
   Lorazepam 
   Consider midazolam infusion (if lorazepam required more than q 3 hours) 
   Note agitation caused by delirium may be worsened by benzodiazepine 
    Consider use of anti-psychotic 
  Non-Pharmacologic 
   Low lighting 
   Soothing music 
   Familiar people/objects 
   Decrease sensory stimuli 
   Provide developmentally appropriate supportive therapy 
 
 Nausea/Vomiting 
  Pharmacologic 
   1st line:  ondansetron or granisetron 
   2nd line:  lorazepam 
   3rd line: prochlorperazine, haloperidol, metoclopramide, dexamethasone 
  Non-Pharmacologic 
   Avoid irritating foods and smells 
            154 
Consider etiology/source of nausea when selecting agent 
   Be aware of distinction between true reduction in nausea versus sedation 
 
 Pain 
  Pharmacologic 
   Opioid with appropriate loading dose 
   Reassess patient frequently 
   Consider repeat doses q 20  min x 3 doses 
   After 3 doses consider continuous infusion 
 
   Once pain is adequately controlled with intermittent dosing 
   Consider switching to continuous infusion 
    Determine 24 hour opioid use (OME) 
    Consider starting with 50% OME, calculate hourly rate 
 
   For patients already on a continuous infusion with symptom escalation 
    Adjust rate no more often than every 8 hours 
    Add total prn boluses 
    Divide by the number of hours over which those boluses were  
     given 
             
    Divide again by 2 (50% reduction) 
    Add to current basal rate, adjust prn dosing based on new hourly  
     Rate 
 
    General Considerations: 
No ceiling dose for opioids in EOL symptom management 
Dosing interval for intermittent dosing may need to be shortened to achieve comfort 
Take into account other possible sedating medications 
Consider long-acting opioids that may not yet have achieved steady state (e.g. methadone, 
fentanyl TD) 
Consider expected course/nature of pain, anticipated procedure etc. 
Consider adjunctive medications and non-pharmacologic interventions 
Consider opioid rotation if significant adverse effects 
 
  Non-Pharmacologic 
   See measures for agitation/anxiety 
   Consider other integrative therapies 
    Acupuncture, biofeedback, guided imagery, mindfulness, 
     Meditation, aromatherapy 
 
Phases of Death          155 
 Pre-Active 
  Withdrawal from active participation in social activities 
  Increased and prolonged periods of sleep 
  Hypersensitivity to stimulation (e.g. light, sound, touch) 
  Decreased appetite and PO intake 
  Increased restlessness, confusion, agitation 
 Active 
  Circulation 
   Blood pressure goes down, heart rate faster, pulse weaker 
   Cold extremities, profound mottling of skin, cyanosis 
  Fluids and metabolism 
   Inability to tolerate enteral nutrition 
   Decreased energy requirements 
   Notable decrease in urine and stool output, bowel or bladder 
incontinence 
  Respiratory 
   Changes in breathing pattern 
    Cheyne-Stokes breathing 
    Agonal breathing 
    Prolonged periods of apnea 
   Inability to close mouth or constant breathing through mouth 
   Difficulty managing secretions, gurgling/noisy breathing  (“death rattle”) 
  Neurologic 
   Unresponsive or responsive only to significant stimulation 
   Limited purposeful movement 
   Decreased muscle tone 
   May experience a sudden unexplained surge of energy 
   “Terminal Agitation” severe multifactorial distress 
    Rule out other confounding variable: 
     Urinary retention, Constipation, Medication toxicity 
   Unable to speak despite appearing awake 
  Senses 
   Hearing may remain intact until death 
    Be cognizant of what is said around patient 
   Vision is blurred 
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1. Acute onset or fluctuation of mental status:    0 for absent 
Is the patient different than his/her baseline mental status?  1 for present 
Has the patient had any fluctuation in mental status in the last 24  
 hours as evidenced by fluctuation on a sedation/level of 
   consciousness scale (such as RASS or GCS)? 
2. Inattention        0 for absent 
Say to the patient, “I am going to read you a series of 10 letters.     (correct 8 or more) 
Whenever you hear the letter “A”, indicate by squeezing my hand.” 1 for inattention 
Read letters from the following letter list in a normal tone 3 seconds     (correct 4-7) 
apart.  “SAVEAHAART”  (Errors are counted when patient fails to 2 for severe inattention 
squeeze on the letter “A” or when the patient squeezes on any       (correct 0-3) 
letter other than “A.”) 
3. Altered Level of Consciousness      0 for absent 
Present if the actual Richmond Agitation-Sedation Scale     (RASS:0) 
Score is anything other than alert and calm (zero)   1 for altered level 
           (RASS:1, -1) 
          2 for severe altered 
            (RASS:>1, <-1) 
4. Disorganized Thinking       0 for absent 
Yes/No questions:         (correct 4 or more) 
    Will a stone float on water?      1 for disorganized 
     Are there fish in the sea?         (correct 2-3) 
    Does one pound weigh more than two pounds?   2 for severe 
    Can you use a hammer to pound a nail?      (correct 0-1) 
Errors are counted when the patient incorrectly answers a question. 
 
Command: Say to patient “Hold up this many fingers” (Hold two  
Fingers in front of patient).  “Now do the same with the other hand” 
(Do not repeat number of fingers) 
 
An error is counted if patient is unable to complete entire command 
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